

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Study - A multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (The VARIANT Trial) study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034708
Article Type:	Protocol
Date Submitted by the Author:	02-Oct-2019
Complete List of Authors:	Clark, Emma; Newcastle University, Northern Institute for Cancer Research Morton, Miranda; Newcastle University, Newcastle Clinical Trials Unit Sharma, Shriya; Newcastle University, Newcastle Clinical Trials Unit Fisher, Holly; Newcastle University, Institute for Health and Society Howel, Denise; Newcastle University, Institute of Health & Society Walker, Jenn; Newcastle University, Newcastle Clinical Trials Unit Wood, Ruth; Newcastle Clinical Trials Unit, Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit Marshall, John Bahl, Amit; University Hospitals Bristol NHS Foundation Trust Crabb, S; University of Southampton Jain, Suneil; Queen's University Belfast Pedley, Ian; Newcastle Upon Tyne Hospitals NHS Foundation Trust Jones, Rob; University of Glasgow Staffurth, John; Velindre Cancer Centre, Research; Cardiff University School of Medicine, Division of Cancer and Genetics Heer, Rakesh; Northern Institute for Cancer Research
Keywords:	Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Prostate disease < UROLOGY, Adult oncology < ONCOLOGY, Urological tumours < ONCOLOGY, Cell biology < BASIC SCIENCES

SCHOLARONE™
Manuscripts

1
2
3 1 **Title**
4

5 2 The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Study - A multicentre
6 3 randomised feasibility trial of biomarker-guided personalised treatment in patients with
7 4 advanced prostate cancer (The VARIANT Trial) study protocol.

9 5 Authors: Emma Clark¹, Miranda Morton², Shriya Sharma², Holly Fisher³, Denise Howel³,
10 6 Jenn Walker², Ruth Wood², Helen Hancock², Rebecca Maier², John Marshall⁴, Amit Bahl⁵,
11 7 Simon Crabb⁶, Suneil Jain⁷, Ian Pedley⁸, Rob Jones^{9*}, John Staffurth^{10*} and Rakesh Heer^{1*}

12 8 *Joint senior authors

- 13 9
14 10 1. Northern Institute for Cancer Research, Newcastle University, Newcastle
15 11 Upon Tyne, UK
16 12 2. Newcastle Clinical Trials Unit, Newcastle University, Newcastle Upon Tyne, UK
17 13 3. Institute for Health and Society, Newcastle University, Newcastle Upon Tyne, UK
18 14 4. VARIANT Trial patient representative
19 15 5. University Hospitals Bristol NHS Foundation Trust
20 16 6. University of Southampton
21 17 7. Queen's University Belfast
22 18 8. The Newcastle upon Tyne Hospitals NHS Foundation Trust
23 19 9. University of Glasgow
24 20 10. Velindre Cancer Centre, Cardiff University, Cardiff, UK

25 21 Corresponding authors:

26 22 1. Emma Clark:

27 23 • e-mail: emma.clark@ncl.ac.uk

28 24 • Phone: 0191 208 4456

29 25 2. Rakesh Heer:

30 26 • e-mail: rakesh.heer@ncl.ac.uk

31 27 • Phone: 0191 208 4300

32 28 Key Words:

- 33 29 • Prostate Disease
34 30 • Protocols and guidelines
35 31 • Adult Oncology
36 32 • Urological tumours
37 33 • Cell biology

38 34 This study opened to recruitment on the 09/07/2019 with the first patient consented
39 35 29/07/2019 and is expected to report in 18 months. This protocol is the current approved
40 36 VARIANT protocol Version 2.0 8th March 2019
41 37

38 Abstract

39 **Introduction:**

40 Prostate Cancer is the most common male cancer with 1 in 4 developing non-curable metastatic
41 disease. Initial treatment responses to hormonal therapies are transient and further management
42 options lie between (1) further hormone therapy or (2) a non-hormonal approach involving
43 additional chemotherapy or molecular radiotherapy (radium-223). There is no clear rationale
44 for choosing between these mechanistically different treatment approaches. The biology of
45 hormone resistance is driven through abnormal androgen receptor activity and we can assay
46 this through a blood test measuring androgen receptor variant 7 (AR-V7) expression in
47 circulating tumour cells (CTCs). Despite increasing evidence supporting AR-V7's role as a
48 prognostic marker, the clinical utility of such measures remains unknown in helping
49 personalise treatment decisions.

50 **Methods and Design:**

51 The VARIANT feasibility trial is a pragmatic design, to be run over 18 months with
52 participants randomised into the intervention arm receiving biomarker (AR-V7) guided clinical
53 treatment and participants randomised into the control arm with conventional standard
54 management (no biomarker guidance). AR-V7 positive participants (likely to be insensitive to
55 further hormone treatment) will receive chemotherapy or in other cases radium-223 (where
56 routinely available). Seventy male ≥ 18 years old participants with metastatic castrate resistant
57 prostate cancer clinically indicated to proceed to further hormone therapy or chemotherapy will
58 be recruited from three National Health Service (NHS) Trusts based in England, Scotland and
59 Wales. The feasibility primary outcome is willingness of patients to be randomised and
60 clinicians to recruit to a biomarker-based treatment strategy, with trial data informing the basis
61 of a definitive and appropriately powered randomised control trial (RCT).

62 **Ethics and Dissemination:**

63 Formal ethics review was undertaken with a favourable opinion, through Wales NRES
64 Committee 2 18/WA/0419. Findings to be disseminated through patient and professional
65 organisations that have expressed their support, media outlets and peer-reviewed journal
66 publication.

67 Article Summary

68 **Strengths and limitations of this study:**

- 69 • **Focuses on a priority area of need in advanced prostate cancer clinical practice.**
- 70 • **To date, the feasibility of delivering a randomised biomarker guided-treatment**
71 **trial in prostate cancer to formally assess clinical utility is not established and will**
72 **be addressed in this study.**
- 73 • **As a feasibility study, the planned sample size (70 participants) does not have**
74 **sufficient power or precision to compare the 'event' rate between treatment arms,**
75 **but will allow informed planning for a definitive randomised controlled trial with**
76 **prominent clinicians from non-recruiting centres involved in feasibility to aid with**
77 **follow-on trial.**

- 78 • **Emerging evidence points to additional Androgen Receptor (AR) biology driving**
79 **hormone resistance, such as other variant expression and mutations – these along**
80 **with alternative biomarkers can be explored in the associated biobanked samples**
81 **(including cell free tumour DNA).**
- 82 • **Strong patient and public involvement to inform study design with a clear**
83 **commitment to informing participants of project outcomes setting a clear new**
84 **gold standard for PPI.**

85 **INTRODUCTION**

86 **Background**

87 Prostate cancer (PC) is the most common male cancer in the UK and the second highest cause
88 of male cancer death(1). In large part, PC is a slowly progressive disease and when detected at
89 an early stage is managed by active surveillance, surgery or radiotherapy. However, 25% of
90 patients will present with, or will progress to, advanced metastatic PC(2,3). Metastatic PC is
91 incurable, with less than one third of patients surviving more than 5 years(1).

92 Medical castration (commonly referred to as hormonal treatment or androgen deprivation
93 therapy (ADT)), blocks production of the hormone testosterone and/or targets the androgen
94 receptor (AR) signalling axis that drives cancer cell growth. Although a good response to
95 hormonal treatment seen often initially, disease progression to a lethal metastatic Castration-
96 Resistant Prostate Cancer (mCRPC) is common(4). Clinical trials have shown that the addition
97 of chemotherapy (docetaxel) or other hormonal approaches (abiraterone acetate or
98 enzalutamide) to initial hormonal therapy have led to a substantial improvement (i.e. delay) in
99 time to the development of mCRPC and overall survival (OS)(8-9). Furthermore, promising
100 recent evidence from randomised trials of androgen-receptor axis-targeted drugs (ARATs)
101 have shown addition of Apalutamide (an inhibitor of the ligand-binding domain of the AR)
102 alongside hormone therapy results in longer overall survival and radiographic progression free
103 survival compared to placebo(10). However despite these rapid advances, mCRPC typically
104 manifests within 3 years and is uniformly fatal(11-13).

105 **Treatment management for mCRPC**

106 Management pathways for mCRPC are still evolving in response to emerging new treatments
107 however, it broadly follows one of two standard care approaches(14): (1) further hormonal
108 treatment such as abiraterone or enzalutamide or (2) ‘non-hormonal’ treatment, typically
109 chemotherapy or molecular radiotherapy (radium 223) (where available). There is no clear
110 biological rationale for choosing between these mechanistically different treatment approaches.
111 Suitable patients for this study can receive both approaches in a sequential manner if one is
112 failing. Patients and clinicians often prefer hormonal treatment, being less toxic and easier to
113 manage, however, only 30-50% of men respond well, with the remainder demonstrating a poor
114 or an equivocal response(15,16). As many patients will not respond to either treatment
115 approach, there are considerable costs from our current management pathways, both in terms
116 of patient experience and outcomes (side effects and disease progression) and economic costs
117 to the NHS (large burden of expensive treatments for the commonest male cancer).
118 Personalised management pathways are urgently needed.

119 **Biology of the Androgen Receptor (AR selective treatment pressure)**

3

1
2
3 120 A breakthrough in understanding the biology of PC revealed that hormonal treatments generate
4 121 a selective pressure at the cellular level inducing complex molecular mechanisms characterised
5 122 by an adaptation of the androgen-AR signalling axis. This results in tumour resistance mediated
6 123 by the induced expression of alternative types of androgen receptor. These AR mRNA splice
7 124 variants lack the important hormone-binding domain, resulting in a constitutively active
8 125 cellular receptor, despite castration. The most widely studied variant is AR-V7(17,18). AR-V7
9 126 activity is not affected by 'hormonal treatment' such as enzalutamide and abiraterone that target
10 127 the hormone-binding domain, potentially rendering these treatments ineffective in men with
11 128 AR-V7(19-21). A surge in ARATs available for clinical use (e.g. Apalutamide and
12 129 Darolutamide) will most likely enhance this burden (although of note, evidence demonstrating
13 130 reduced effectiveness of these treatment in men who are positive for AR-V7 or other variant
14 131 splice forms including AR point mutations, have not been published to date).

18 19 132 **Rationale**

20
21 133 Published clinical data demonstrates a strong link between AR-V7 expression and mCRPC
22 134 progression and highlights the potential for AR-V7 to be utilised as a treatment stratification
23 135 biomarker to identify those men likely to be sensitive to further hormonal treatment (AR-V7-
24 136 ve patients) and avoid futile treatments in those predicted to be insensitive (AR-V7+ve
25 137 patients)(21-29). Notably AR-V7 positivity is not associated with insensitivity to taxane
26 138 chemotherapy treatment (relative reduction in risk of death of 76% maintained with
27 139 chemotherapy, hazard ratio: 0.24; 95% CI, 0.10-0.57; P = 0.035)(27,30) and data from the
28 140 recent PROPHECY trial reports on the prognostic value of the AR-V7 biomarker (prospective
29 141 observational cohort of poor prognosis patients with advanced prostate cancer who receive
30 142 abiraterone or enzalutamide treatment)(31). The commercially available AdnaTest
31 143 ProstateCancerPanel AR V7 assay (Qiagen®) detects AR-V7 mRNA expression in circulating
32 144 tumour cells (CTCs) in whole blood and has been independently and robustly clinically
33 145 validated in terms of reproducibility and comparisons of sensitivity and specificity with other
34 146 AR-V7 detection platforms(31,41-44). However to date, there have been no formal measures
35 147 of the clinical utility of AR-V7 as a predictive biomarker

39 40 148 **Evidence gap**

41
42 149 Encouragingly, a cost saving analysis of performing ProstateAdnaTest AR-V7 biomarker
43 150 testing in mCRPC demonstrated use of the biomarker would result in a substantial cost saving
44 151 as long as the true prevalence of AR-V7 was >5% (well below the accepted prevalence rate of
45 152 30%)(45). However, formal cost effectiveness analyses based on incremental cost-
46 153 effectiveness ratio (ICER) (cost per quality-adjusted life year gained) and assessing prevalence
47 154 rates of this biomarker have yet to be carried out.

48
49
50 155 The National Comprehensive Cancer Network Task Force(32) and CRUK consensus statement
51 156 on biomarker roadmap for cancer studies(33) have highlighted the key recommendations for
52 157 accelerating a tumour biomarker into clinical practice by sequentially demonstrating evidence
53 158 for; (1) analytic reproducibility; (2) clinical validity and; (3) clinical utility. Previous clinical
54 159 studies on AR-V7 testing focused on retrospective or prospective cohort analyses of associated
55 160 AR-V7 expression distinguishing subgroups with different clinical outcomes with hormonal
56 161 treatment in men with metastatic PC(23,26,29,30,34-38). However, the highest level of
57 162 assessment of clinical worth in improving patient outcomes (clinical utility) remains lacking.

1
2
3 163 We have paid particular focus to address clinical utility evidence gaps in the VARIANT trial
4 164 using published levels of evidence standards for assessing biomarkers to inform study design.
5 165 We aim to demonstrate improvement in patient outcome sufficiently to justify AR-V7
6 166 biomarker incorporation into routine clinical care (including feasibility of collecting quality of
7 167 life measures for a future health economic evaluation)(39,40).

10 168 **Emerging treatment landscape**

11
12 169 The treatment landscape of hormone sensitive (PC) is evolving, altering treatment pathways
13 170 for mCRPC. Recent data from the USA based PROPHECY trial reporting on a prospective
14 171 observational cohort showed mRNA AR-V7 (modified Qiagen ProstateCancerAdnaTest,
15 172 Baltimore, MD) and protein AR-V7 (Epic nuclear-specific, San Diego) biomarker positivity
16 173 associated with worse progression free survival (PFS) and overall survival (OS) in poor
17 174 prognosis patients with advanced prostate cancer who receive abiraterone or enzalutamide
18 175 treatment (31). Criticisms of the study included lack of testing with alternative treatment such
19 176 as chemotherapy (which we have addressed in this study) and pre-selection of high risk CRPC
20 177 patients (i.e. those with poor prognosis), ultimately generating results that cannot be
21 178 extrapolated over the overall CRPC population (46-49). Of note, lower AR-V7 prevalence was
22 179 reported in the overall CRPC population in the ARMOR3-SV phase III clinical trial which
23 180 employed the Adnatest ProstateCancerSelect and Detect CTC assay (Qiagen®) to assess AR-
24 181 V7 mRNA expression, where only 8% of men were AR-V7 positive (95% CI 6-10)(42,43).

25
26
27
28
29 182 We argue however, irrespective of the evolving treatment landscape, the opportunity to
30 183 generate feasibility data for a biological (biomarker) informed approach to treatment selection
31 184 over standard care protocol-based approaches, tests a highly relevant clinical question in these
32 185 high risk CRPC patients (i.e. those who have more to lose from pursuing a ‘try and see’
33 186 approach). This would provide an appealing long-term strategy (for patients and service
34 187 providers) to ultimately improve on clinical outcome (specifically for a clinical subgroup of
35 188 poor prognosis patients, identifying those likely to be sensitive to further hormonal treatment
36 189 and avoid futile treatments in those that are predicted to be insensitive).

39 190 **Main Aim of Study**

40
41 191 To determine the feasibility of conducting a definitive randomised control trial to evaluate the
42 192 clinical utility of an AR-V7 blood biomarker assay in personalising treatment for men with
43 193 mCRPC in UK NHS clinical practice.

45 194 **Objectives**

46 195 Feasibility study

48 196 **Primary:**

- 49 197 1. To establish if it is feasible to conduct a definitive trial comparing AR-V7 biomarker-
50 198 driven management with the current standard care in patients with mCRPC.

53 199 **Secondary Objectives:**

- 54
55
56 200 2. To estimate AR-V7 biomarker prevalence in the trial population to inform sample size
57 201 calculations for a definitive randomised control trial.

- 1
2
3 202 3. To assess recruitment, compliance and retention rates
4 203 4. To confirm outcome measures for a future definitive trial and establish trial data
5 204 response rates, variability, and data quality.
6 205 5. To establish a blood sample biorepository to include baseline, 12 and 24 week blood
7 206 samples for future translational studies.

8
9
10 207 **Exploratory objectives:**

- 11 208 6. To establish a complete serial blood tissue archive to include potential measures of cell
12 209 free DNA and additional AR-Variants in CTCs and cfDNA biomarker measures (such
13 210 as AR mutations, other AR splice forms and AR amplification and other mutations such
14 211 as PTEN/p53/MYC gain/RB1 loss/MET gain and further molecular pathways yet to be
15 212 defined) to complement AR-V7 reads, depending upon the ultimate biomarker
16 213 performance characteristic established in this trial population. Blood will be collected,
17 214 processed and archived at 0 weeks (baseline), 12 weeks and 24 weeks following the
18 215 first treatment.
19 216 7. To explore thresholds of the magnitude of AR-V7 positivity to investigate relationships
20 217 with outcomes and to estimate AR-V7 positivity rate assumptions regarding a cut-off
21 218 point.
22 219 8. To undertake cross site validation of biomarker reads between two GCP laboratories
23 220 (NICR, Newcastle and AWMGL, Cardiff).
24 221
25
26
27
28
29

30 222 **METHODS AND ANALYSIS**

31 223 **Study design**

32 224 This feasibility study is a multi-centre, two-arm, randomised control trial (RCT). All patients
33 225 who consent to take part in the trial and who are eligible, will have a blood test to assess
34 226 prevalence rate of the AR-V7 biomarker. Participants will be randomised in the ratio 1:1 to
35 227 receive personalised standard treatment (intervention) guided by AR-V7 biomarker status or
36 228 standard care (control) without biomarker guided treatment. Those in the control group will
37 229 not receive blood biomarker test results.
40

41 230 The treatment for each patient is expected to be dependent on various factors (e.g. clinician
42 231 choice, patient choice, previous treatments, co-morbidities, concomitant medication and
43 232 pattern of disease) as well as randomised allocation and AR-V7 status in the personalised
44 233 treatment arm. All treatments are part of standard care for these participants. Treatment options
45 234 for participants randomised to the personalised standard treatment arm will be recommended,
46 235 but not mandated within this feasibility trial, with reasons for not following the
47 236 recommendation recorded and reported as outcome. A CONSORT diagram of study protocol
48 237 (version 2.0 8th March 2019) is shown in figure 1.

49 238 **Study Setting**

50 239 Seventy patients with mCRPC who require a change in treatment will be recruited in three
51 240 secondary care NHS Trusts in the UK spread across England (The Newcastle upon Tyne
52 241 Hospitals NHS Foundation Trust), Scotland (NHS Greater Glasgow and Clyde) and Wales
53 242 (Velindre University NHS Trust). We aim to recruit mCRPC patients with a predicted poor
54 243 overall survival. We anticipate this group of mCRPC patients have the most to gain from a
55
56
57
58
59
60

6

244 biological-based treatment approach as their disease is more likely to progress during a period
245 of treatment with an inactive agent. Multivariate analysis from the metastatic population of
246 STAMPEDE(52) has shown that worse overall survival was seen in men with the following
247 features: presence of bone metastases (regardless of soft tissue metastases), worse WHO
248 performance status (0 vs 1 or 2), higher (or unknown) initial Gleason sum score category (≥ 8
249 vs ≤ 7), and younger age at randomisation < 60 yrs. Poorer failure free survival (but not overall
250 survival was additionally seen in men with worse primary tumour stage and higher PSA level
251 before starting ADT. There is overlap between these poor prognostic features and factors
252 associated with a high likelihood of harbouring AR-V7+ve CTCs(43,44).

253 **Eligibility Criteria**

254 Patients will be aged ≥ 18 years old with metastatic castrate resistant prostate cancer (high risk
255 features) clinically indicated to proceed to further hormone therapy or chemotherapy and fulfil
256 all of the following criteria:

- 257 1. Histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
- 258 2. Radiographic and/or histological and/or cytological evidence of metastatic disease.
- 259 3. Castrate levels of testosterone and documented ongoing medical or surgical castration.
260 Testosterone level ≤ 50 ng/dl /1.73 nmol/L and maintaining on androgen suppression
261 therapy
- 262 4. Disease progression since the last change in therapy defined by one or more of the
263 following: (i) PSA progression as defined by the prostate cancer working group 3
264 (PCWG3) criteria ≥ 2 ng/ml; (ii) bone disease progression as determined by the local
265 radiology/ multidisciplinary team; (iii) radiographic progression of nodal or visceral
266 metastases as determined by the local radiology/ multidisciplinary team.
- 267 5. Suitable for treatment with at least one novel hormonal treatment (with available
268 treatments abiraterone acetate or enzalutamide) and one non-hormonal therapy (with
269 available treatments docetaxel, cabazitaxel or radium-223).
- 270 6. At least two high risk features: (i) age < 60 years at time of diagnosis of metastatic
271 disease; (ii) bone metastases present at time of initial metastatic prostate cancer
272 diagnosis (although not mandated, it is considered good clinical practice to have up to
273 date imaging within 8 weeks); (iii) Gleason grade group 4 or 5 (Gleason score 8 to 10);
274 (iv) presence of visceral metastases (e.g. liver or lung) at any time point. This does not
275 include lymph node metastases; (v) PSA doubling time < 3 months; (vi) elevated
276 alkaline phosphatase above institutional upper limit of normal; (vii) ECOG
277 Performance Status worse than or equal to 1; (viii) previous treatment for castration
278 resistant prostate cancer with docetaxel chemotherapy; (ix) previous treatment for
279 castration resistant prostate cancer with abiraterone and/or enzalutamide or equivalent
280 agent.
- 281 7. Estimated life expectancy > 6 months.
- 282 8. Provision of written informed consent, including consent for bio-banking of blood
283 samples.

284 Exclusion Criteria applied in the VARIANT trial are:

- 285 1. Histological variants of prostate cancers with small cell or neuroendocrine features.
- 286 2. Prior or current malignancy (except adenocarcinoma of the prostate) with an estimated
287 $\geq 30\%$ chance of relapse/progression within next 2 years.
- 288 3. Previously identified brain metastases or spinal cord compression unless treated with
289 full functional recovery.
- 290 4. Administration of an investigational agent within 30 days of first dose of trial
291 medication.

292 **Randomisation**

293 Patients will be randomised to receive either personalised standard treatment (guided by AR-
294 V7 biomarker status) or standard care (not guided by biomarker status) on a 1:1 basis using a
295 method of random permuted blocks of concealed variable block size and stratified by site.

296 **Study Intervention**

297 This three-centre randomised feasibility study incorporates a control and an intervention arm.
298 All patients will undergo AR-V7 biomarker assessment with results only made known to the
299 patients and clinical team in the intervention arm.

300 **Intervention arm**

301 Treatment will be given as per standard care with recommendations guided by biomarker
302 status; (1) If the participant is found to be AR-V7 positive, then non-hormonal treatment is
303 recommended (docetaxel chemotherapy, cabazitaxel chemotherapy or radium-223 therapy) or
304 (2) if the participant is found to be AR-V7 negative, then next generation hormonal treatment
305 is recommended (either enzalutamide or abiraterone).

306 The results of the AR-V7 biomarker assessment will be provided securely to the clinical team
307 to enable tailored treatments based on AR-V7 expression from the biomarker result. Where a
308 decision is made that the participant will receive a non recommended therapy (either by the
309 clinician or patient), this therapy, and the reasons for giving this will be documented.

310 **Control arm**

311 Participants with their clinical care team will make an informed and preference-based decision
312 to receive standard care, including either next generation hormone treatments abiraterone or
313 enzalutamide or non-hormonal approaches including docetaxel or cabazitaxel chemotherapy
314 or radium-223. Details of all treatment administered, including doses, will be recorded as part
315 of the trial.

316 The research team at sites will not receive the participants AR-V7 biomarker results.

317 **Outcome Measures**

318 Standardised clinical assessment tools used in monitoring CRPC disease and progression on
319 treatment will be reported (listed in box 1). Primary outcome measures are related to feasibility
320 (recruitment, retention and adherence) and will report the following;

- 321 (1) the proportion of prostate cancer patients identified through clinics who meet the eligibility
322 criteria;
- 323 (2) the number of patients accrued per site per month over the course of the trial;
- 324 (3) baseline prevalence of AR-V7 expression in the participant cohort (this will be presented
325 as a crude percentage of AR-V7 positivity of total participants, and in each arm);
- 326 (4) the willingness of patients to be randomised (defined as the proportion of patients
327 consenting to be randomised from all eligible patients approached about the study);

- 328 (5) compliance rate (this will be defined as the number of patients who start randomised
 329 treatment as a proportion of the number randomised);
 330 (6) the proportion of patients who: start AR-V7 recommended treatment; start treatment other
 331 than the recommended treatment; change treatment before disease progression; or withdraw.
 332 (This measure will capture information regarding patients who choose not to take
 333 recommended treatment because of strong preferences and patients who progress rapidly while
 334 waiting for treatment with a change in eligibility for treatment options).
 335 (7) the proportion of trial participants with assessable blood samples for biomarker status
 336 (which would affect treatment targeting);
 337 (8) the median time from the blood sample being drawn to; (i) AR-V7 result being sent back
 338 to the site and (ii) patient starting treatment (and compared with standard of care treatment).
 339 (9) the proportion of randomised patients for whom data is collected on each clinical and health
 340 economic outcome at baseline, 12 and 24 weeks.

Box 1 Standardised Clinical Assessment Tools

Clinical Outcome Measures:

(1) Time to PSA progression; (i) Confirmed rising PSA more than 12 weeks after randomisation. (*Where there has been a decline in PSA from baseline, progression will be a 25% or greater increase, and an absolute increase of at least 2ng/mL, from the nadir, which is confirmed by a second value obtained 3 or more weeks later. Where no decline from baseline is documented, progression must be a 25% or greater increase from the baseline value along with an increase in absolute value of 2 ng/mL or more. In all cases, the initial rise in PSA must occur after a minimum of 12 weeks from randomisation.*)

(2) Clinical progression and survival within 6-months; (i) Number of patients who have progressed clinically at 6-months (includes change of systemic anti-cancer therapy and death from PC); (ii) Cancer specific survival at 6-months; and (iii) overall survival at 6-months.

(3) Quality of life for patients with cancer (EORTC QLQ-C30).

(4) Additional quality of life items patients with prostate cancer (EORTC QLQ-PR25).

(5) Participant costs questionnaire (Use of Health Services Questionnaire).

342 Further information on recruitment, screening, the patient consent procedure and informed
 343 consent literature can be found in the supplementary section.

Data collection

345 Table 1 shows a trial schedule of events. A more detailed description of all data collection
 346 including a data management plan, can be found in the supplementary section. In summary, in
 347 addition to collecting standard care assessment of disease status data from patients in the
 348 intervention and control arms, trial specific questionnaire assessment (EORTC QLQ-C30
 349 Quality of Life of Cancer Patients, EORTC QLQ-PR25 Quality of Life Prostate Cancer
 350 Module) will take place at the baseline, 12 and 24 week visit.

Procedure	Screening	VISIT 1 Consent/ Baseline	VISIT 2 12 weeks	VISIT 3 24 weeks

			(+/- 2 weeks)	(+/- 2 weeks)
Medical History and Demographics	X			
Record results of standard care PSA test	X	X	X	X
Eligibility Assessment	X ^a	X ^a		
Patient Information Sheet	X			
Informed consent		X		
Testosterone if no previous confirmation		X ^b		
Confirmation of eligibility		X ^a		
Randomisation		X		
Access to standard of care haemoglobin and biochemistry results		X		
Blood sample collection and shipment for CTC/ctDNA blood assessment and AR-V7 analysis (analysed at NICR labs)		X	X	X
CTC blood sample collection and shipment for cross site validation ^c (analysed at All Wales Medical Genetics Lab)		X ^c		
EORTC QLQ-C30/PR25 Questionnaires		X		X
AR-V7 blood test result feedback to patient ^d		X ^d		
Use of Health Services Questionnaire				X
Anti-cancer therapy review			X	X
Clinical assessment of disease status			X	X

351 Table 1. Trial Schedule of Events

352 a = Eligibility assessment performed against trial eligibility criteria in screening, patients likely
 353 to be eligible will be given a VARIANT Information Sheet and trial information. Eligibility

354 will be confirmed by an Investigator (medically qualified doctor) after patients have provided
355 written informed consent and before randomisation.

356 b = in those cases where there is no previous confirmation of castrate levels of testosterone
357 only. These patients will not be randomised until castration is confirmed and the patient is
358 documented as eligible.

359 c = for selected patients only (confirmed at randomisation), for cross site validation of AR-V7
360 status

361 d = for patients randomised to the personalised standard treatment arm (guided by AR-V7
362 biomarker) only.

363 **AR-V7 biomarker measure**

364 A validated two-centre pipeline (consisting of preanalytical, analytical and postanalytical
365 phases) to measure AR-V7 biomarker using the commercially available AdnaTest
366 ProstateCancerPanel AR-V7 circulating tumour cell (CTC) quantitative RT-PCR (RT-qPCR)
367 assay (Qiagen®) (intended for molecular biology applications), has been set up according to
368 assay manufacturers recommendations, analytical methods and sponsor agreed SOP's.
369 Following biomarker data analysis and data verification, for participants randomised to the
370 intervention standard treatment arm (AR-V7 biomarker guided), the baseline biomarker result
371 and biomarker treatment recommendation will be sent securely within 10 working days to the
372 local PI and delegated research staff. Further information on the specifics of AR-V7 biomarker
373 driven personalised treatment (sample receipt, processing, analysis and reporting of read-out)
374 can be found in the supplementary section.

375 **Data Analysis Plan**

376 Analyses will be conducted on an intention-to-treat basis, with sensitivity analyses used to
377 investigate the impact of non-compliance to allocated arm. Given the feasibility status of this
378 study, all statistical analyses will be descriptive. The majority of the outcome data will be
379 presented in simple descriptive tables presenting percentages, means and standard deviations
380 or 5-number summary (as appropriate), for each arm of the study. Analysis of clinical and
381 biomarker measures will be assessed by; (1) clinical progression and survival within 6-months;
382 (2) PSA response/progression (confirmed rising PSA more than 12 weeks after randomisation);
383 (3) clinical progression and survival (overall and cancer specific) within 6-months (includes
384 change of cancer therapy for progression); and (4) survival (overall and progression free)
385 estimates will be derived using the Kaplan Meier method and presented as 6-month rates with
386 confidence intervals. The relationship between survival estimates and continuous AR-V7
387 biomarker expression will be modelled considering non-linear transformations in a univariate
388 Cox model, or parametric alternative, presented as parameter estimates (HR) with confidence
389 intervals.

390 Compliance with quality of life and health economic measures will be assessed by; (1) number
391 of patients completing measures as a proportion of the number randomised; (2) degree of
11

1
2
3 392 completeness of each domain of the EORTC QoL and economic questionnaire measures. These
4 393 scores will be presented graphically and with numeric descriptive statistics. Data Management

6 394 **Study statistical size calculations**

8
9 395 This trial is designed as feasibility trial according to definition of Eldridge *et al.*(53). Feasibility
10 396 includes the deliverability of the intervention and in this case, assessment of the frequency of
11 397 the positive assay measurements (predicted at approximately 30%). It has been recommended
12 398 that data in an external pilot trial is collected on a minimum of 60 patients per arm to estimate
13 399 the ‘event’ rate(54). However, we plan to calculate a pooled estimate of overall recruitment
14 400 rate, and overall biomarker prevalence rate, and will recruit 70 patients in total to allow for
15 401 attrition.

17
18
19 402 The performance of potential outcome measures for a definitive trial will be assessed by
20 403 estimating data completeness of the instruments and any potential bias in the completion of
21 404 follow-up data. This information will be used to inform the design, choice of outcomes,
22 405 necessary sample size and approach to the analysis, of a future definitive trial.

24 406 **Safety Reporting**

25
26
27 407 This is a low risk trial and no specific safety reporting is required. Should an Investigator have
28 408 any concern regarding participant safety as an outcome of their participation in the trial, they
29 409 will contact the Trial Management Group (TMG) and Chief Investigator as soon as possible.
30 410 The Trial Oversight Committee (TOC) will monitor concerns as required.

32 411 **Trial Conduct and Governance**

33
34
35 412 The trial will be conducted in accordance with the UK Policy Framework for Health and Social
36 413 Care and, as applicable, the Guidelines for Good Clinical Practice. The TMG is responsible for
37 414 the day-to-day management of the trial, overseeing all aspects of the conduct of trial to ensure
38 415 that the protocol is adhered to and take appropriate actions to ensure patient and data safety.
39 416 The TOC will review trial conduct and accumulating clinical trial data and provide overall
40 417 supervision for the trial on behalf of the Sponsor and the Funder. The constitution of the TMG
41 418 and TOC including roles and responsibilities delegation for this trial can be found in the
42 419 supplementary section. Aggregated data will be analysed by the Trial Statisticians and reported
43 420 to an external independent TOC at least annually.

47 421 **Public and Patient Involvement**

48
49
50 422 The design, planning and management of this trial has been supported by two prostate cancer
51 423 patient representatives (co-applicant on the funding grant and TMG member), both have
52 424 advocated the dissemination of trial findings to patients and ensured that the public was
53 425 adequately considered during trial design. PPI has been embedded into the study, with the
54 426 patient’s voice a strong theme to inform and influence the on-going research and development
55 427 of participant information resources in collaboration with the ‘Cancer Perspectives’ patient
56 428 representative group (Newcastle upon Tyne Hospitals NHS Foundation Trust). A strong

429 commitment is to inform the participants of the outcome of this project, a clear new gold
430 standard for PPI.

431 **Ethics and dissemination**

432 Favourable ethical opinion has been obtained from the Wales National Research Ethics Service
433 (NRES) Committee 2 18/WA/0419. All parties will conduct the trial in accordance with this
434 ethical opinion. No amendment to protocol will be made without consideration and approval
435 by the Trial Management Committee.

436 Feasibility data will be published as a peer-reviewed article and if successful, these findings
437 will contribute to gaining further funding for a HTA full trial. In addition, assessing clinical
438 data and blood derivatives from the participant cohort will provide valuable material
439 (circulating tumour cells CTCs, transcript & plasma ctDNA), to validate translational studies
440 of other AR aberrations and hormone targeting resistance pathways (or the emergence of
441 biomarkers for chemo-sensitivity), to inform and contribute further to the rapidly evolving
442 treatment developments for CRPC. Participants will remain anonymised in all publications.

443 We will also utilise dissemination through patient and professional organisations that have
444 expressed their support for this trial (PCF, CRUK, NCRI Prostate CSG and BAUS) and through
445 media outlets including web resources, lay press, academic national and international
446 conferences and peer-reviewed journal publication.

447 Trial registration number: ISRCTN10246848

448 **Figure legends**

449 Figure 1 VARIANT trial consort diagram. Planned flow of participants throughout the
450 VARIANT study. mCRPC, Metastatic Castrate Resistant Prostate Cancer; PSA, Prostate
451 Specific Antigen; EORTC-QLQ-C30/PR25, European Organisation for Research and
452 Treatment of Cancer Quality of Life Questionnaire; AR-V7, Androgen Receptor Variant 7.

453 **References**

- 454 1. Cancer Research UK (CRUK). Prostate Cancer Statistics. Electronic citation. [accessed 2019
455 August]. Available from: [https://www.cancerresearchuk.org/health-professional/cancer-](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer)
456 [statistics/statistics-by-cancer-type/prostate-cancer](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer).
- 457 458 2. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'era MA. No improvement noted in
459 overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-
460 year period. *Cancer*. 2014;120(6):818-23.
- 461 462 3. Public Health England. Cancer Information Tools. Electronic citation. [accessed 2019 Aug].
463 Available from: http://www.ncin.org.uk/cancer_information_tools.
- 464 465 4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. *Nat*
466 *Rev Cancer*. 2001;1(1):34-45.

- 1
2
3 468 5. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition
4 469 of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer
5 470 (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised
6 471 controlled trial. *Lancet*. 2016;387(10024):1163-77
7 472
- 8 473 6. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al.
9 474 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term
10 475 Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. *J Clin Oncol*.
11 476 2018;36(11):1080-87
12 477
- 13 478 7. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al.
14 479 Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *N Engl J*
15 480 *Med*. 2017;377(4):338-351
16 481
- 17 482 8. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al.
18 483 Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J*
19 484 *Med*. 2017;377(4):352-360
20 485
- 21 486 9. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide
22 487 with Standard First-Line Therapy in Metastatic Prostate Cancer. *N Engl J Med*.
23 488 2019;381(2):121-31.
24 489
- 25 490 10. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al.
26 491 Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*.
27 492 2019;381(1):13-24.
28 493
- 29 494 11. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, et al. Efficacy
30 495 of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association
31 496 between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration
32 497 of ADT effect. *Cancer*. 2008;112(6):1247-53.
33 498
- 34 499 12. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et
35 500 al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *N Engl J*
36 501 *Med*. 1998;339(15):1036-42.
37 502
- 38 503 13. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A
39 504 controlled trial of leuprolide with and without flutamide in prostatic carcinoma. *N Engl J Med*.
40 505 1989;321(7):419-24.
41 506
- 42 507 14. ASCO. Practice Guidelines. [https://www.asco.org/practice-guidelines/quality-guidelines/
43 508 guidelines/genitourinary-cancer](https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer). Accessed 13/10/2016.
44 509
- 45 510 15. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone
46 511 in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*. 2013;368(2):138-
47 512 48.
48 513
- 49 514 16. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival
50 515 with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*. 2012;367(13):1187-
51 516 97.
52 517

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

517

17. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. *Endocr Relat Cancer*. 2011;18(5):R183-96.

520

18. Luo J. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. *Asian J Androl*. 2016;18(4):580-5.

523

19. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. *Endocr Relat Cancer*. 2014;21(4):T87-T103.

527

20. Beltran H, Antonarakis ES, Morris MJ, Attard G. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. *Am Soc Clin Oncol Educ Book*. 2016;35:131-41.

531

21. Maughan BL, Antonarakis ES. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. *Curr Treat Options Oncol*. 2015;16(12):57.

534

22. Daniel M, Dehm SM. Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. *J Steroid Biochem Mol Biol*. 2016.

537

23. Stone L. Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker. *Nat Rev Urol*. 2016;13(8):433.

540

24. Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. *Oncotarget*. 2016.

543

25. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. *Ann Oncol*. 2015;26(9):1859-65.

547

26. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. *Oncotarget*. 2015.

550

27. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. *JAMA Oncol*. 2016.

554

28. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer Res*. 2009;69(1):16-22.

559

29. Antonarakis ES, Lu C, Wang H, Lubber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance

561

to enzalutamide and abiraterone in prostate cancer. *N Engl J Med*. 2014;371(11):1028-38.

562

563

- 1
2
3 564 30. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen Receptor
4 565 Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-
5 566 Resistant Prostate Cancer. *JAMA Oncol.* 2015;1(5):582-91.
6 567
- 7 568 31. Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, et al.
8 569 Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone
9 570 Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY
10 571 Study. *J Clin Oncol.* 2019;37(13):1120-9.
11 572
- 12 573 32. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, et al. NCCN
13 574 Task Force report: Evaluating the clinical utility of tumor markers in oncology. *J Natl Compr*
14 575 *Canc Netw.* 2011;9 Suppl 5:S1-32; quiz S3.
15 576
- 16 577 33. O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, et al. Imaging
17 578 biomarker roadmap for cancer studies. *Nat Rev Clin Oncol.* 2017;14(3):169-86.
18 579
- 19 580 34. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, et al. Expression of
20 581 androgen receptor splice variants in prostate cancer bone metastases is associated with
21 582 castration-resistance and short survival. *PLoS One.* 2011;6(4):e19059
22 583
- 23 584 35. Antonarakis ES. Predicting treatment response in castration-resistant prostate cancer: could
24 585 androgen receptor variant-7 hold the key? *Expert Rev Anticancer Ther.* 2015;15(2):143-5.
25 586
- 26 587 36. Antonarakis ES, Luo J. Prostate cancer: AR splice variant dimerization-clinical
27 588 implications. *Nat Rev Urol.* 2015;12(8):431-3.
28 589
- 29 590 37. De Laere B, van Dam PJ, Whittington T, Mayrhofer M, Diaz EH, Van den Eynden G, et al.
30 591 Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-
31 592 resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant
32 593 Expression Patterns. *Eur Urol.* 2017;72(2):192-200
33 594
- 34 595 38. Siewerts AM, Mostert B, van der Vlucht-Daane M, Kraan J, Beaufort CM, Van M, et al.
35 596 An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7
36 597 mRNA Expression in Circulating Tumor Cells. *J Mol Diagn.* 2018;20(3):316-25.
37 598
- 38 599 39. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, et al. Tumor
39 600 marker
40 601 utility grading system: a framework to evaluate clinical utility of tumor markers. *J Natl Cancer*
41 602 *Inst.* 1996;88(20):1456-66.
42 603
- 43 604 40. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and
44 605 predictive biomarkers. *J Natl Cancer Inst.* 2009;101(21):1446-52.
45 606
- 46 607 41. Todenhofer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kuhs U, et al.
47 608 Preliminary experience on the use of the Adnatest(R) system for detection of circulating tumor
48 609 cells in prostate cancer patients. *Anticancer Res.* 2012;32(8):3507-13.
49 610
- 50 611 42. Attard G, Borre M, Gurney H, Loriot Y, Andresen C, Kalleda R, et al. ASCO 2017: Clinical
51 612 factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone vs

- 1
2
3 613 enzalutamide in men with AR-V7+ metastatic castration-resistant prostate cancer. Abstract
4 614 2017 ASCO Annual Meeting. June 2-6, 2017, Chicago.
5 615
6 616 43. Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein BA, Saad F, et al.
7 617 Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of
8 618 galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant
9 619 prostate cancer (mCRPC). *J Clin Oncol*. 2017;35:15_suppl, 5005-5005
10 620
11 621 44. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. Clinical Significance of
12 622 Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with
13 623 Metastatic Castration-Resistance Prostate Cancer Treated with First- and Second-Line
14 624 Abiraterone and Enzalutamide. *J Clin Oncol*. 2017;35(19):2149-56
15 625
16 626 45. Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-savings analysis of
17 627 AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for
18 628 treatment with abiraterone or enzalutamide. *Prostate*. 2016.
19 629
20 630 46. Sharp A, Porta N, Lambros MBK, Welti JC, Paschalis A, Raj GV, et al. Dissecting
21 631 Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced
22 632 Prostate Cancer. *J Clin Oncol*. 2019;37(24):2182-4.
23 633
24 634 47. De Laere B, Ost P, Gronberg H, Lindberg J. Has the PROPHECY of AR-V7 Been
25 635 Fulfilled? *J Clin Oncol*. 2019;37(24):2181-2.
26 636
27 637 48. Dirix L. Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With
28 638 Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study. *J Clin Oncol*.
29 639 2019;37(24):2180-1.
30 640 49. Armstrong AJ, Halabi S, Luo J, Nanus DM, Scher HI, Antonarakis ES, et al. Reply to L.
31 641 Dirix, B. De Laere et al, and A. Sharp et al. *J Clin Oncol*. 2019;37(24):2184-6
32 642
33 643 50. Van Etten JL, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, et al. Targeting a Single
34 644 Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor
35 645 mRNA Splice Variants in Prostate Cancer. *Cancer Res*. 2017;77(19):5228-35
36 646
37 647 51. Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, et al. Truncation and constitutive
38 648 activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. *Nat*
39 649 *Commun*. 2016;7:13668
40 650
41 651 52. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with
42 652 Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients
43 653 in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). *Eur Urol*.
44 654 2015;67(6):1028-38
45 655
46 656 53. Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al.
47 657 Defining Feasibility and Pilot Studies in Preparation for Randomised Controlled Trials:
48 658 Development of a Conceptual Framework. *PLoS One*. 2016;11(3):e0150205.
49 659
50 660 54. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size

1
2
3 661 requirements to estimate key design parameters from external pilot randomised controlled
4 662 trials: a simulation study. *Trials*. 2014;15:264.

5 663
6 664 55. Zhang J, Cunnigham JJ, Brown JS and Gatenby RA. Integrating evolutionary dynamics
7 665 into treatment of metastatic castrate-resistant prostate cancer. *Nat Commun*. 2017;8(1):1861

8 666 **Acknowledgments**

9
10
11 667 We would like to acknowledge the valuable support of the VARIANT Trial Oversight
12 668 Committee (TOC) members Dr Alison Tree, Dr Andrew Feber, Dr Rhian Gabe and our
13 669 patient representatives on this committee Robin Millman and Paul Nash. We are grateful for
14 670 the assistance and support of our scientific collaborators Scott Dehm (University of
15 671 Minnesota), Luke Gaughan (NICR), Jun Luo (John Hopkins), Gert Attard (UCL) and the All
16 672 Wales Medical Genetics Laboratory (AWMGL).

17
18
19 673 Management of the study is by Newcastle University Clinical Trial Unit (NCTU).

20
21 674 **Authors' contribution**

22
23 675 Emma Clark: Conception and design of the work, data collection, drafting of the article,
24 676 critical revision of the article and final approval of the version to be published

25
26 677 Miranda Morton: Trial management, data collection and drafting of the article.

27
28 678 Shriya Sharma: Trial management, data collection and drafting of the article.

29
30 679 Holly Fisher: Conception and design of the work, drafting of the article and critical revision
31 680 of the article.

32
33 681 Denise Howel: Data collection, drafting of the article, critical revision of the article and final
34 682 approval of the version to be published.

35
36 683 Jenn Walker: Trial management and data collection.

37
38 684 Ruth Wood: Trial management, data collection, drafting of the article data collection, critical
39 685 revision of the article and final approval of the version to be published

40
41 686 Helen Hancock: Critical revision of the article and final approval of the version to be
42 687 published.

43
44 688 Rebecca Maier: Critical revision of the article.

45
46 689 John Marshall: Conception and design of the work, critical revision of the article and final
47 690 approval of the version to be published.

48
49 691 Amit Bahl: conception and design of the work.

50
51 692 Simon Crabb: conception and design of the work and critical revision of the article.

52
53 693 Suneil Jain: conception and design of the work and critical revision of the article.

54
55 694 Ian Pedley: conception and design of the work, data collection, critical revision of the article
56 695 and final approval of the version to be published

1
2
3 696 Rob Jones: conception and design of the work, data collection, drafting of the article, critical
4 697 revision of the article and final approval of the version to be published
5

6 698 John Staffurth: conception and design of the work, data collection, drafting of the article,
7 699 critical revision of the article and final approval of the version to be published
8

9 700 Rakesh Heer: conception and design of the work, drafting of the article, critical revision of
10 701 the article and final approval of the version to be published
11

12
13 702 **Funding statement**

14 703 This work was supported by a National Institute for Health Research (NIHR) Research for
15 704 Patient Benefit (grant number PB-PG-0816-20043). The PHOTO trial is sponsored by
16 705 Newcastle upon Tyne Hospitals National Health Service Foundation Trust.
17
18

19 706 **Competing Interests Statement**

20
21 707 JS reports non-financial support from Bayer and personal fees from Janssen and Astellas
22 708 outside of the submitted work. SC has an honoraria/advisory role with Roche, Clovis
23 709 Oncology, Bayer, Janssen Cilag and Merck and receives research support from AstraZeneca,
24 710 Astex Pharmaceuticals and Clovis Oncology.
25

26 711 **Word Count (excluding title page, tables and reference list): 4, 364**
27
28
29
30 712
31 713




Figure 1 VARIANT trial consort diagram. Planned flow of participants throughout the VARIANT study. mCRPC, Metastatic Castrate Resistant Prostate Cancer; PSA, Prostate Specific Antigen; EORTC-QLQ-C30/PR25, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; AR-V7, Androgen Receptor Variant 7.

Supplementary Data – VARIANT Protocol

The constitution of the Trial Management Group (TMG): Chief Investigator, Sponsor representative, Co-Lead Investigator, Laboratory and Translational Science Lead, Statistician Lead, Trial Management Team, Co-Applicants and Collaborators who will attend TMG meetings as required.

The constitution of the Trial Oversight Committee (TOC) as a combined TOC whose members are independent of the trial: independent Chair, Independent Lab representative, Independent statistician and two independent patient representatives.

Roles and Responsibilities

Chief Investigator - Dr Rakesh Heer, Senior Lecturer and Consultant Urological Surgeon, Northern Institute for Cancer Research, Newcastle University

Co-Lead Investigator - Prof. John Staffurth, Professor in Oncology and Consultant Oncologist, Velindre Cancer Centre, Cardiff University

Laboratory and Translational Science Lead - Dr Emma Clark, Translational Research Associate, Northern Institute for Cancer Research, Newcastle University

Principle Investigator - Prof Rob Jones, Professor of Clinical Cancer Research/ Honorary Consultant in Medical Oncology, University of Glasgow

Principle Investigator - Dr Ian Pedley, Clinical Director of NCCC and Clinical Oncologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust

Co-applicants – (1) Dr Amit Bahl, Senior Lecturer, Consultant Oncologist and Clinical Director, University Hospitals Bristol NHS Foundation Trust; (2) Dr Simon Crabb, Associate Professor and Honorary Consultant in Medical Oncology, University of Southampton; (3) Dr Suneil Jain, Senior Lecturer and Consultant in Clinical Oncology, Queen's University Belfast.

PPI Representative - Dr John Marshall

Senior Statistician - Denise Howel, Institute of Health and Society, Newcastle University

Statistician - Dr Holly Fisher, Institute of Health and Society, Newcastle University

Data Manager – Ruth Wood, Newcastle Clinical Trials Unit, Newcastle University

Senior Trial Manager – Jenn Walker, Newcastle Clinical Trials Unit, Newcastle University

Joint Trial Manager - Dr Miranda Morton and Shriya Sharma, Newcastle Clinical Trials Unit, Newcastle University

Sponsor - The Newcastle upon Tyne Hospitals NHS Foundation Trust

Funder - National Institute for Health Research – Research for Patient Benefit

Supplementary Data – VARIANT Protocol

Out of Hours Contact - Dr Rakesh Heer, Newcastle University

Trial Oversight Committee (TOC) Chair - Dr Alison Tree, Uro-oncology Trials Team Leader and Consultant Clinical Oncologist, The Institute of Cancer Research

Recruitment and screening

Patients will be approached during routine clinic appointments from urology or oncology clinical services. Potentially eligible patients will have the trial explained to them, provided with a Patient Information Sheet (PIS) and their medical notes reviewed to establish if they are likely to be eligible to take part in the trial. In addition to assessing patient eligibility against the inclusion and exclusion criteria, a complete medical history including the patient's age and detailed information about their prostate cancer history and metastases will be collected after consent.

Consent Procedure

Full written informed consent will be received by signing, dating and initialling the consent form, which will be witnessed by a member of the research team, who has documented and delegated responsibility, and will check eligibility and counter-sign the consent form. The participant will specifically consent to; (1) their GP being contacted and informed of participation in the study; (2) access to relevant sections of their medical notes to carry out follow-up after the trial has ended; and (3) serial collection of blood samples for biomarker testing and storage in the Androgen Receptor Biology Bio-Bank (AR-3B) biobank for up to 10 years after the trial has ended.

Data collection methods

In addition to collecting standard care assessment of disease status data from intervention and control groups, trial specific questionnaire assessment (EORTC QLQ-C30 Quality of Life of Cancer Patients, EORTC QLQ-PR25 Quality of Life Prostate Cancer Module) and blood sample collection will take place at baseline, 12 and 24 week visits. Use of Health Services Questionnaire will be completed end of trial assessments. Participant data will only be identified using a unique individual participant identifier.

Standard care assessments:

The following clinical assessments will be conducted;

1. Cause of death (if appropriate)
2. Evidence of PSA progression (>25% and >2 ng/mL above the nadir and confirmed by a second value >3 weeks later)
3. Clinical evidence of progression, stage and type of progression (biochemical, radiological or symptomatic)
4. Result of routinely collected PSA and testosterone measurements, full blood count and biochemistry tests

Supplementary Data – VARIANT Protocol

- 1
2
3 5. Details of anti-cancer therapy, including dates of treatments for ongoing anti-cancer
4 therapy.
5
6

Questionnaires:

7
8
9
10 The EORTC quality of life questionnaire is an integrated system for assessing the health-related
11 quality of life (QOL) of cancer patients participating in clinical trials. There is a set of core
12 questions (QLQ-C30), supplemented by a prostate cancer specific module (PR25). PR25 is a
13 diagnosis-specific module designed to be used in conjunction with the QLQ-C30, it is intended
14 for use among a wide range of patients with prostate cancer varying in disease stage and
15 treatment modality.
16
17

18
19 The QLQ-C30 consists of thirty questions incorporating; (1) functional scales, symptom scales
20 and a number of items assessing additional symptoms commonly reported by patients with
21 cancer, assessed on a four point scale and (2) a global health status/quality of life scale, assessed
22 on a seven point scale. The PR25 module consists of 25 questions incorporating functional and
23 symptom scales, all assessed on four point scale. The Use of Health Services questionnaire
24 consists of ten questions assessing participant's use of health services over the course of their
25 participation in the trial.
26
27
28

Data Management and Archiving

29
30
31 Data including the number of patients screened, approached and interested in taking part will
32 be collected via a screening log. Trial and screening data is collected on electronic case report
33 forms (eCRFs) using password limited access, secure web-based interface for data entry with
34 inbuilt back-up facility, will be managed using a Clinical Data Management System (Elsevier's
35 MACRO™) overseen by the Newcastle Clinical Trials Unit (NCTU). Individual access will be
36 limited according to delegated roles and duties. Data will be handled, computerised and stored
37 in accordance with the UK Data Protection Act 2018. All trial data will be retained in
38 accordance with the latest Directive on GCP (2005/28/EC).
39
40
41
42

43 Participant clinical information will not be released without the written permission of the
44 participant, except as necessary for monitoring and auditing by the Sponsor, its designee,
45 Regulatory Authorities, the Trial oversight committee (TOC) or the Research Ethics
46 Committee (REC). Trial data will be released to the trial statistician for analysis, to NICR
47 biobank researchers after trial analysis and used in planning any future, definitive trial. All trial
48 data will be stored for 10 years, in accordance with GCP and sponsor approved SOPs.
49
50
51


AR-V7 biomarker driven personalised treatment pipeline

52
53
54 Biomarker driven personalised treatment will be based on current scientific evidence from the
55 Adnatest assay biomarker founding lab (John Hopkins, Baltimore, USA). A biomarker positive
56 result is when a read is detected at 35 qPCR cycles or less and the recommendation will be to
57 proceed with chemotherapy. A biomarker negative result is when a read is detected over 35
58
59
60

Supplementary Data – VARIANT Protocol

qPCR cycles (or there is no read at any qPCR cycle), and the recommendation will be to proceed with hormonal therapy (Enzalutamide or Abiraterone).

Participants will be required to give 30ml of blood at baseline (0 weeks), 12 weeks and 24 weeks. Samples will be routinely processed for biomarker read-out and AR-3B biobank storage at the Northern Institute for Cancer Research (NICR) central analysis lab as detailed in the VARIANT biomarker flow chart below. Following biomarker data analysis and data verification (according to sponsor agreed analytical and validation plan and SOPs), for participants randomised to the intervention standard treatment arm (AR-V7 biomarker guided), the baseline biomarker result and biomarker treatment recommendation will be sent securely within 10 working days to the local PI and delegated research staff. The PI and local trial team will then communicate with the participant regarding the biomarker guided treatment. Any modifications to the recommended treatment for participants will be made at the discretion of the treating clinician, based on their clinical judgement. Biomarker results from blood samples taken at weeks 12 and 24 will not be made available to the PI, local trial team or participant.



For participants randomised to the standard treatment arm (not AR-V7 biomarker guided), biomarker results will not be made available to the PI, local trial team or participant for any of the blood samples analysed (baseline, week 12 and week 24).

AR-V7 biomarker cross-site validation

An additional twenty participants selected at randomisation will provide a further (10ml) blood sample for cross site validation analysis of the biomarker at All Wales Medical Genetics Laboratory (AWMGL) using the commercially available AdnaTest ProstateCancerPanel AR-V7 circulating tumour cell (CTC) quantitative RT-PCR (RT-qPCR) assay (Qiagen®).

Androgen Receptor Biology driving hormone resistance

Supplementary Data – VARIANT Protocol

Research suggests that key ‘sub-populations’ or clones of molecular alterations (of which AR-V7 is an important subtype), compete with each other and are drivers of treatment resistance. In addition to performing AR-V7 biomarker assay, a fuller capture of AR-related CRPC biology will be achieved by collecting CTCs, plasma, buffy coat and red blood cell derivatives to compile an Androgen Receptor Biology Bio-Bank (AR-3B). Whole and CTC depleted blood sample derivatives will be collected and biobanked at 12 weekly intervals from baseline (prior to treatment) throughout follow up (to a maximum of 24 weeks +/- 2 weeks), including all trial captured data.

It is also important to acknowledge the expression of other AR splice variants are also associated with resistance to hormonal treatment(50,51), as are other AR pathway alterations such as AR mutations and amplifications(37). Ongoing discussions in the field as to the discriminatory value of solely detecting AR-V7 expression, may ultimately lead to a combination test that will improve treatment stratification and patient outcomes. However, at this time, AR-V7 remains the forerunner and a formal understanding of biomarker characteristics in the advanced prostate cancer treatment setting is required ‘to best inform’ a formal large-scale testing.

The AR-3B biorepository resource will be used to assess total VARIANT expression (capturing all VARIANTS in a single qPCR reaction) and explore (but not be limited to) AR hot spot mutations/sequencing/amplification and other mutations such as PTEN/p53/MYC gain/RB1 loss/MET gain/PARPi and further molecular pathways based on yet to be defined but new emerging data in time, in blood and blood derivatives.

This resource will provide added value to the feasibility study, by banking processed biomarker tissue for additional biomarker measures that may also contribute to hormone targeting resistance (or the emergence of biomarkers for chemo-sensitivity), and importantly be relevant in prostate cancer management. Blood samples will be transported, stored, accessed and processed in accordance with sponsor approved SOPs following appropriate legislation relating to the use and storage of human tissue for research purposes and such activities shall at least meet the requirements as set out in the 2004 Human Tissue Act and 2006 Human Tissue (Scotland) Act.

The results of any other research utilising blood samples (including those in the control arm), will not be reported back to the clinical team or to participants, this data is for research purposes only and will be published in appropriate peer reviewed scientific journals. Participants will remain anonymised in all publications.

Androgen Receptor Biology Bio-Bank (AR-3B) sample storage governance

Samples will be appropriately labelled in accordance with trial protocol as described in the current VARIANT trial site blood collection manual (Version 1.0 28th March 2019) to comply with the General Data Protection Regulation (GDPR) and Data Protection Act (GPA) 2018 and pseudo-anonymised with linkage to participant details possible only through the Participant Identification Log assessable only to delegated personnel. Sample shipment will be tracked and

Supplementary Data – VARIANT Protocol

sample receipt at central analysis labs recorded using a specific sample collection MACRO™ database which is separate to the main trial database.

All AR-3B biobank samples are stored under HTA license 12534, under the Designated Individual, Dr. Christopher Morris (NICR). All samples are held under the custodianship of Mr. Rakesh Heer (Chief Investigator), who is responsible for the curation of these samples and ensuring compliance with the Human Tissue Act (2004) and GCP. Samples will be tracked and stored using Achiever medical LIMS.

Blood samples sent to AWMGL will be consumed within 7 days of receipt and are not under the remit of the HTA. All RNA and DNA derivatives will be transferred to the NICR AR-3B biorepository for storage at the end of the trial.



To be printed on local headed paper

PATIENT INFORMATION SHEET

The Variant 7 Biomarker Feasibility Study

The VARIANT Study

We are inviting you to take part in a research study

Please read the following information to help you decide if you want to take part. It will explain why we are doing this research and what it might mean for you. You are free to decide whether or not to take part in this study. You do not have to decide straight away and you can talk to your friends/family about it. Ask us if you have any questions or you want to know more. If you choose not to take part, this will not affect the care you get from your doctors.

Study Summary

- In this study we will be taking 3 blood samples and asking patients to complete some questionnaires during their usual hospital appointments.
- Patients with **advanced metastatic prostate cancer** (cancer that has spread from the prostate to other parts of the body), often eventually stop responding to initial hormone therapy. After this point, treatment is usually with either:
 - 1) **Further hormonal treatment called next generation hormone treatment OR**
 - 2) **Non-hormonal treatment such as chemotherapy or radiotherapy**
- There is currently no clear guidance for which of these two different standard care treatment options a patient should receive.
- Testing the level of AR-V7 (a type of protein) in blood could suggest which of these two treatments patients will respond to best. The AR-V7 test is known as a biomarker test.
- VARIANT is looking to find out if the AR-V7 biomarker test is helpful to support doctors and patients in choosing between these treatment options.
- In this study, half of patients will receive treatment guided by the AR-V7 biomarker test. The other half will receive treatment as usual.

Please read the following information to see if you may be interested in taking part.

What is a biomarker test?

Biomarkers are substances that can be found and measured in parts of the body, in this case, the blood. Biomarker testing is a type of test that looks for these substances to give doctors information about a patient's health. **The AR-V7 blood test is a biomarker test looking for the AR-V7 protein.**

Why is VARIANT needed?

Initial treatments for advanced metastatic prostate cancer include hormone treatment alone or chemotherapy in combination with hormone treatment. Eventually most patients with advanced prostate cancer stop responding to initial hormone treatment. At this point, patients usually receive treatment with either further hormone treatment, known as next generation hormone treatment (such as abiraterone or enzalutamide), or with non-hormonal options (typically chemotherapy, or in some cases radium-223 radiotherapy). Although there are fewer side effects associated with next generation hormone treatment relative to chemotherapy, only 30-50% of patients will respond well to further hormone treatment.

The **AR-V7 biomarker is found in the blood** of some men who have received initial hormone treatment for prostate cancer. Recent studies have suggested that patients who have this biomarker in their blood may be less likely to respond well to advanced hormone therapy. Measuring the amount of this biomarker in blood (which is not usually tested for), may be useful to help guide choice of treatment for patients with advanced metastatic prostate cancer. We hope this will improve patient experience and outcome by spending less time on and experiencing side effects of treatments that might not work, starting a different treatment earlier, and potentially reduce the cost to the NHS.

The VARIANT study is a feasibility study in which we will look at whether doctors and patients are willing to use the results of this blood test to decide on a treatment option. At this stage we do not know that the AR-V7 biomarker will lead to patients having better responses to treatments. However, we hope that the results of VARIANT will help us to plan a similar, but larger, study to find out if the AR-V7 blood test does result in better outcomes for patients and whether AR-V7 testing should be used in standard NHS practice. We hope that 70 patients will take part in VARIANT.

Why have I been invited to take part?

You have been diagnosed with advanced metastatic prostate cancer and have already been treated with hormone therapy (also known as androgen deprivation therapy, or ADT). Your disease has stopped responding to the current therapy and you are due a change in treatment plan.

Do I have to take part?

No, it is up to you to decide if you want to take part in VARIANT. If you do not want to take part, you will still get the standard treatment that has been arranged by your treating doctor.

If you agree to take part, you can change your mind and withdraw from the study at any time without having to give a reason.

What does taking part involve?

- If you decide to take part, you will be selected to have either:

a) treatment guided by AR-V7 blood test result

In this group, your treating doctor will receive the results of your AR-V7 blood test. Your treating doctor will tell you the result of the AR-V7 blood test and discuss this with you before arranging a treatment option for you. The results of the test may support you and your doctor in deciding whether next generation hormonal therapy or non-hormonal therapy would be more suitable for you.

b) treatment as usual

In this group, your doctor will arrange a treatment option with you as they usually would if you were not in the study. You and your treating doctor will NOT receive the results of your AR-V7 blood test. The results will only be looked at by the trial management team at the end of the study.

- You will have equal chance of being in group a) or group b) (a 50:50 chance). Your group will be selected by a computer. We call this 'randomisation'. Your doctor will not have any say over which group you are in.
- It is important to note that we are not testing a new treatment in this study. All VARIANT patients will receive one of the usual treatment options available to patients in the NHS. The study is looking at whether doctors and patients are willing to use the AR-V7 blood test and whether it is helpful in deciding **which** treatment option is most suitable for individual patients.

What will I have to do?


A member of the VARIANT team will discuss the study with you and answer any questions you may have. If you decide to take part, and your doctor confirms you are eligible for the study, you will be asked to sign a consent form.

As well as receiving the treatment arranged with your doctor, taking part in the study will mean (for ALL patients, that is patients in group a) and group b)):

- You will be asked to give a **blood sample on 3 occasions** (at the start of the study, after 12 weeks and 24 weeks). We would like to collect around 20 ml of blood (about 4 teaspoons full) each time.
- Some patients will be selected to give an **additional blood samples on one occasion** (at the start of the study). We would like to collect around 10 ml of blood (about 2 teaspoons full) for this sample. Patients will be randomly selected by a computer system to give this additional blood samples. The doctor or a member of their team will tell you if you have been selected to give this sample.

- On 2 of these visits, you will be asked to complete 2 **short questionnaires** about your quality of life. These will take around 15 minutes each to complete.
- Study visits will all take place during your usual hospital visits. There should be no extra visits to hospital required.
- We will use some information that is already collected about you as part of your standard clinical care. This includes information about your diagnosis, your treatment, results of scans and blood tests and your physical health. Taking part in VARIANT does not involve any extra scans to those you would receive normally.
- To take part in VARIANT, you will be asked to give your permission for your blood samples collected during this study to be stored at the Northern Institute of Cancer Research and used for future research as described below.

Study timeline in addition to standard treatment



What will happen to my blood samples?

Your blood samples will be tested for the AR-V7 biomarker at the Northern Institute for Cancer Research (NICR). If you are selected to give the additional blood sample this will be sent to the All Wales Medical Genetics Laboratory (AWMGL) for testing. You and your treating doctor will only find out the AR-V7 biomarker result if you are selected to have your treatment guided by the AR-V7 blood test result.

After the AR-V7 test, any remaining sample will be stored at the NICR biobank (a collection of samples) and will be used in future research to look at why people develop advanced prostate cancer and how cancer reacts to treatments. If you do not want your samples to be stored or used through the NICR biobank you will not be able to take part in this trial.

Your samples will be labelled with a unique study number. This number is used to link your sample back to you and only the study team and authorised people will be able to do this. Your sample will be sent with a form that includes your initials, date of birth and the date the sample was taken. This will help us make sure the samples can be linked back to the correct person.

For more detailed information about what will happen with your blood samples please see the section 'Further information about what will happen to blood samples' on page X, we recommend that you read this.

Expenses and payments

You will not receive payment for taking part in VARIANT. All parts of the study will happen when you are already coming to hospital for your usual visits.

What happens when the research study stops?

Your appointment at 24 weeks will be the last time we see you for the study. At the end of the study you will continue to receive usual clinical care as decided by your hospital and doctor. If appropriate, this may include continuing the anti-cancer drugs you are receiving, or changing to another if you and your doctor believe this to be in your best interests.

What are the possible risks and benefits of taking part?

Risks: Taking blood samples may cause some discomfort and minor pain, and occasionally patients can feel faint during or after. Sometimes patients will have some bruising where the blood has been taken. Only trained members of staff will perform the blood tests and every effort will be made to prevent any discomfort.

VARIANT patients will receive one of the usual treatment options available to patients in the NHS. Your doctor will be able to tell you more about possible side effects of these treatments. The risk of these treatments is the same as if you were not taking part in the study.

Benefits: By taking part in VARIANT, you will be helping us gather information to learn about using the AR-V7 biomarker to guide treatment for patients with advanced metastatic prostate cancer. We hope that we can improve the quality of life of patients in the future from VARIANT.

For some patients, taking part in the study will mean that your doctor receives your AR-V7 biomarker result before deciding on a treatment for you. This may help to inform which treatment would be best for you after reviewing your medical history.

If you want to find out more about taking part in research studies, you can visit the NHS Choices Website www.nhs.uk/conditions/clinical-trials/. On this website you will also find contact details for your local Patient Advice Liaison Service (PALS) office if you would like to speak to someone.

Further supporting information

What will happen if I do not want to carry on in the study?

You can withdraw your consent at any time and for any reason, without having to tell us your reason. You will be fully cared for and supported as per your hospital's standard practice.

We will ask if you are happy for us to:

- Use any information already collected about you.
- Continue using information collected as part of your usual care until the end of the study.

1 You can change your mind about allowing your stored blood samples to be used for
2 research at any time in the future, without giving any reasons, by contacting your local
3 study team as listed on page x. Any samples left at the NICR will be destroyed. Any
4 researchers to whom samples have been sent will be instructed to destroy the samples
5 they have in their laboratories. It will not be possible to withdraw any findings from
6 research work already undertaken using your donated samples.
7
8
9

10 **Can I take part in other research?**

11
12 If you are already taking part in a clinical trial we would look to see what the trial involved
13 and speak to the other trials team. We would need check that taking part in one trial would
14 not affect the treatment or results in the other.
15
16

17 If you take part in VARIANT and want to join another trial in the future, we ask that you
18 let the VARIANT team know so we can check with their team that there is no conflict. If
19 there was a conflict, the study team would discuss your options with you and you can
20 decide what it best for you.
21
22
23

24 **What if there is a problem?**

25
26 If you are not happy with any part of VARIANT, you should ask to speak to the study team
27 first who will do their best to help you. **Their contact details are on page X.** If you are still
28 unhappy you may wish to raise your concerns with someone who is not directly involved in
29 your care. You can contact the Patient Advice Liaison Service (PALS) who provide a
30 confidential service on <site to localise with phone number and email address>
31
32
33

34 In the unlikely event that you are harmed during the research and this is due to someone's
35 negligence (they were careless) you may have grounds for legal action for compensation,
36 but you may need to meet your own legal costs. NHS indemnity does not offer no-fault
37 compensation (for harm that is not anyone's fault).
38
39
40

41 **Will my GP be told about my involvement in VARIANT?**

42
43 Yes, with your permission we will inform your GP that you are taking part in VARIANT. We
44 will send you a copy of this letter so that you can see exactly what has been said. It will also
45 be noted in your hospital medical records so that staff in the hospital know you took part in
46 the study.
47
48
49

50 **What will happen to the results of the study?**

- 51 • The study is due to finish at the end of 2020.
- 52 • The results will be written in medical journals and presented in meetings to other
- 53 doctors, nurses and researchers.
- 54 • The anonymised data might be shared with other researchers and to help with future
- 55 studies. Your identity will always be protected.
- 56 • A report will be written by the study funder and put on their website.
- 57
- 58
- 59
- 60

- You may request a summary of the results at the end of the trial by contacting the study team, their details are on page X.

Will the information about me be kept confidential?

Yes. All of the information collected will be entered on computers that are kept secure and password protected.

- We will use a study number to identify you instead of using your name.
- Your contact details will never be shared with anyone else.
- You will not be named in any published results, reports or anything on our website.

The study information about you and your medical notes will be looked at by people directly involved in the study, clinical and lab staff as well as by people who are checking the study is running as it should. This may include the Newcastle Clinical Trials Unit at Newcastle University as they are managing the study. It may also include regulatory authorities, sponsor and funder.

Your local study team will collect information from you during the study. This will be entered onto a secure database using your study number instead of your name. Your local study team will be the only people that know that the study number refers to you. This means that the data on the database it is not identifiable to anyone outside of your local study team. The database is held by the Newcastle Clinical Trials Unit at Newcastle University. Access to this database is password protected and available to your doctors and research staff for the purpose of the trial. Data from the database will be analysed at the end of the whole study. Anonymised data from the database may be used when applying to carry out future related clinical trials or for other research projects related to prostate cancer.

After you have finished attending study visits, your local study team may review your health records and collect information for the study.

Data Protection

All of the data we collect will be kept strictly confidential and in accordance with the General Data Protection Regulation (GDPR).

We have included information on page X of this document that tells you how we do this and included some websites where you can find out more.

Who is organising and funding VARIANT?

The main study doctor (also called the 'Chief Investigator') is Mr Rakesh Heer, a Urological Surgeon at The Newcastle upon Tyne Hospitals NHS Foundation Trust. The study team includes senior doctors and nurses, university experts in research studies, and members of the public.

It is managed by the Newcastle University Clinical Trials Unit on behalf of the study sponsor – The Newcastle upon Tyne Hospitals NHS Foundation Trust. It is funded by the National Institute for Health Research, Research for Patient Benefit programme.

At least 3 hospitals will be taking part in VARIANT. Each hospital has a study doctor, called an 'Investigator'. The Investigator in your hospital is

Who has reviewed the study?

All research in the NHS is looked at by an independent group of people called a Research Ethics Committee. VARIANT has been reviewed and given a favourable opinion by the Wales REC 2 committee.

Patients have been involved in deciding how to do VARIANT from the start. For example, patients were involved in designing and applying for funding for the study, and continue to contribute as part of the study team. We also asked a group of patients and carers who have experienced cancer to look at the study information sheet to check the study is described in a clear way and is easy to understand.

What if relevant new information becomes available?

The treatment management of metastatic prostate cancer is changing all of the time. All VARIANT patients will receive one of the standard treatment options available in the NHS. This will include any new treatment options that become available while the study takes place.

Information gathered during the course of this study will be reviewed by an independent Trial Oversight Committee. The role of this group is to protect the safety and wellbeing of participants by making sure the study is running safely.

What if I have any questions?

Please ask the doctor or nurse who is looking after you. They can put you in touch with the research team or the Investigator for VARIANT at your hospital.

What happens next?

You can take time to think about the study and whether you want to take part. A member of the research team will speak to you when you come back in to discuss your treatment options. They will go through this information sheet with you and answer any questions before you make your final decision.

Thank you for taking the time to read this information sheet.

VARIANT team contact details for your hospital:

Principal Investigator:
Address:

Research Nurse:
Address:

Tel:

Tel:

GDPR and Transparency Information

The Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) is the sponsor for this study based in the United Kingdom and will act as the “data controller” for this study. **They are responsible for looking after your information and using it properly.**

This study is managed on behalf of the sponsor by the Newcastle Clinical Trials Unit who will act as the “data processor”. As data processor, this means that we are responsible for processing personal data on behalf of a controller. We will be using information from you in order to undertake this study, and will keep identifiable information about you for 10 years.

Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the least amount of personally-identifiable information possible.

You can find out more about how your information is used at http://www.newcastle-hospitals.org.uk/about-us/freedom-of-information_how-we-use-information

To find out more about research and general use of patient information please refer to the Health Research Authority Website <https://www.hra.nhs.uk/information-about-patients/>

The sponsor as an NHS Organisation and the Newcastle Clinical Trials Unit as a University use personally-identifiable information to conduct research to improve health, care and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when we use personally-identifiable information from people who have agreed to take part in research. This means that when you agree to take part in a research study, we will use your data in the ways needed to conduct and analyse the research study.

Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the interests of society as a whole. We do this by following the [UK Policy Framework for Health and Social Care Research](#).

If you wish to raise a complaint on how we have handled your personal data, you can contact our Data Protection Officer who will investigate the matter. If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful you can complain to the Information Commissioner’s Office (ICO).

The sponsor Data Protection Officer is Richard Oliver and you can contact them at nuth.dpo@nhs.net.

The local study team at your hospital will collect information from you and/or your medical records for this research study in accordance with our instructions.

The local study team will use your name, NHS number and contacts details to contact you about the research study, and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study. Individuals from the sponsor, Newcastle Clinical Trials Unit and regulatory organisations may look at your medical and research records to check the accuracy of the research study. The local

1 study team will pass these details to the sponsor or the Newcastle Clinical Trials Unit
2 along with information collected from you and/or your medical records. The only people
3 at sponsor or the Newcastle Clinical Trials Unit who will have access to information that
4 identifies you will be people who need to contact you or audit the data collection process.
5 The people who analyse the information will not be able to identify you and will not be
6 able to find out your name, NHS number or contact details.
7

8
9 The local study team will keep identifiable information about you from this study for 10
10 years after the study has finished.
11

12 When you agree to take part in a research study, the information about your health and
13 care may be provided to researchers running other research studies in this organisation
14 and in other organisations. These organisations may be universities, NHS organisations
15 or companies involved in health and care research in this country or abroad. Your
16 information will only be used by organisations and researchers to conduct research in
17 accordance with the UK Policy Framework for Health and Social Care Research.
18
19

20 This information will not identify you and will not be combined with other information in a
21 way that could identify you. The information will only be used for the purpose of health
22 and care research, and cannot be used to contact you or to affect your care. It will not be
23 used to make decisions about future services available to you, such as insurance.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Further information about what will happen to blood samples

- Your samples will be sent securely to the Northern Institute of Cancer Research (NICR) for testing. For selected patients, a sample will also be sent to the All Wales Medical Genetics Laboratory (AWMGL) for testing (to confirm the results of the biomarker test).
- At the start of the study, your blood sample will be tested for the AR-V7 biomarker. Your doctor will receive the result of this test if you are in the group receiving treatment guided by AR-V7 blood test result. If you are in the treatment as usual group neither you nor your doctor will receive the result of the test.
- We may also test your blood sample for the AR-V7 biomarker at the end of the trial. These results will be used to inform the research. Neither you nor your doctor will not receive these results.
- Your blood samples will be stored at the NICR biobank (a collection of samples) and will be used in future research to look at why some patients develop advanced prostate cancer or how the cancer reacts to treatment. The DNA and RNA (the genetic material inside a cell), will be taken out of these stored samples and will also be stored at the NICR biobank. If you do not want your samples to be stored or used through the NICR biobank you will not be able to take part in this trial.
- Although unlikely for the VARIANT trial, there is a small possibility that your blood samples which have been stored in the NICR biobank may be used in research involving rodents (rats or mice). This is only done when it is essential to further our understanding of the way in which a disease develops or responds to treatment. These experiments are performed according to strict guidelines set out by the government and involve minimal stress to the rodents. **If you do not wish for your samples to be used in research using animals you should not complete the box referring to this on the consent form we will ask you to sign.** If you do not consent to your samples being used in research using animals you will still be able to participate in the VARIANT trial.
- If you are selected to provide an additional sample to be sent to AWMGL, the DNA and RNA (the genetic material inside a cell) may be taken out and stored at AWMGL before being transferred to the NICR biobank.
- You and your doctor will not find out the results of any tests done on your stored blood samples. Results of future research with your stored samples will be used to improve care of patients with advanced prostate cancer in the future.
- Your blood samples will be labelled with a unique study number. This number is used to link your sample back to you and only the study team and authorised people will be able to do this. Your sample will be sent with a form that includes your initials, date of birth and the date the sample was taken. This will help us make sure the samples can be linked back to the correct person which is especially important for feeding back the test results.
- Your stored samples may be used by researchers in the UK or overseas (including USA or Europe). Commercial partners may also use your samples for research

1 purposes. In most cases the commercial partners will be small companies that
2 were started in universities (university/academic spin-off companies), or drug
3 companies. Working with commercial partners is often important to have the
4 resource to develop tests or products. We will ask partners to sign a legal contract
5 to make sure samples are handled appropriately. Although the research will not be
6 conducted to make money, it is possible that some of the results will be of value to
7 commercial companies, for example in the development of new tests or treatments
8
9

- 10 • Any money made by sending samples to commercial laboratories will be put in to
11 local research or used to improve patient care. Under UK law, sample donors are
12 not entitled to a share of any profits that may result from this activity.
13
- 14 • The samples will be destroyed after 10 years of the last follow up for the last patient
15 enrolled in the study. This will include all the blood samples and any linked data.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Consent Form



To be printed on local headed
paper

The Variant 7 Biomarker Feasibility Study

The VARIANT Study

PATIENT CONSENT FORM

Site ID number:

Participant ID Number:

Principal Investigator Name: _____

Please INITIAL these boxed if you agree:

1. I have read and understood the Patient Information Sheet version _____ dated _____ for the above study. I have had the opportunity to consider the information, ask questions and I am happy with the answers given.	
2. I understand that I do not have to take part in this study. I know that I can withdraw at any time without giving a reason and without my medical care or legal rights being affected.	
3. I understand that information about me will be collected, recorded and used for this study unless I withdraw my consent. I understand that my information will be kept securely and confidentially.	
4. I agree for a copy of my consent form to be sent securely to the Newcastle University Clinical Trials Unit for checking.	
5. I agree to my General Practitioner (GP) being informed about me taking part in this study.	
6. I understand that relevant sections of my medical notes and information collected during the study may be looked at by people from Newcastle Clinical Trials Unit, the study sponsor, regulatory authorities and the local NHS Trust, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.	

Consent Form

taking consent

When completed: 1 copy for participant; 1 copy (original) for Investigator Site File; 1 copy to be kept in medical notes and 1 copy to be sent securely to Newcastle Clinical Trials Unit

For peer review only

Completed SPIRIT checklist for VARIANT trial protocol submission:

Administrative Information:

1. Title
2. Trial Registration
3. Protocol Version
4. Funding
5. Roles and Responsibilities

Introduction:

6. Background and Rationale
7. Objectives
8. Trial Design

Methods: Participants, interventions, Outcomes

9. Study Setting
10. Eligibility criteria
11. Interventions
12. Outcomes
13. Participant timeline
14. Sample size
15. Recruitment

Methods: assignment of interventions (for controlled trials)

16. Allocation
17. Blinding (masking)

Methods: data collection, management, analysis

18. Data collection methods
19. Data management
20. Statistical methods

Methods: monitoring

21. Data monitoring
22. Harms
23. Auditing

Ethics and dissemination:

24. Research ethics approval
25. Protocol amendments
26. Consent or assent
27. Confidentiality
28. Declaration of interests
29. Access to data
30. Ancillary and post-trial care
31. Dissemination policy

Appendices

32. Informed consent materials
33. Biological specimens

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Study - A multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (The VARIANT Trial) study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034708.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Nov-2019
Complete List of Authors:	Clark, Emma; Newcastle University, Translational and Clinical Research Institute Morton, Miranda; Newcastle University, Newcastle Clinical Trials Unit Sharma, Shriya; Newcastle University, Newcastle Clinical Trials Unit Fisher, Holly; Newcastle University, Population Health Sciences Howel, Denise; Newcastle University, Population Health Sciences Walker, Jenn; Newcastle University, Newcastle Clinical Trials Unit Wood, Ruth; Newcastle Clinical Trials Unit, Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit Marshall, John Bahl, Amit; University Hospitals Bristol NHS Foundation Trust Crabb, S; University of Southampton Jain, Suneil; Queen's University Belfast Pedley, Ian; Newcastle Upon Tyne Hospitals NHS Foundation Trust Jones, Rob; University of Glasgow Staffurth, John; Velindre Cancer Centre, Research; Cardiff University School of Medicine, Division of Cancer and Genetics Heer, Rakesh; Newcastle University, Translational and Clinical Research Institute
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Urology
Keywords:	Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Prostate disease < UROLOGY, Adult oncology < ONCOLOGY, Urological tumours < ONCOLOGY, Cell biology < BASIC SCIENCES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Title**
4

5 2 The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Study - A multicentre
6 3 randomised feasibility trial of biomarker-guided personalised treatment in patients with
7 4 advanced prostate cancer (The VARIANT Trial) study protocol.

9 5 Authors: Emma Clark¹, Miranda Morton², Shriya Sharma², Holly Fisher³, Denise Howel³,
10 6 Jenn Walker², Ruth Wood², Helen Hancock², Rebecca Maier², John Marshall⁴, Amit Bahl⁵,
11 7 Simon Crabb⁶, Suneil Jain⁷, Ian Pedley⁸, Rob Jones^{9*}, John Staffurth^{10*} and Rakesh Heer^{1*}

12 8 *Joint senior authors

13 9 1. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle
14 10 University, Newcastle upon Tyne, UK

15 11 2. Newcastle Clinical Trials Unit, Newcastle University, Newcastle Upon Tyne, UK

16 12 3. Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle
17 13 University, Newcastle Upon Tyne, UK

18 14 4. VARIANT Trial patient representative

19 15 5. Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK

20 16 6. Southampton Experimental Cancer Medicine Centre, University of Southampton,
21 17 Southampton, UK

22 18 7. Radiotherapy Department, Cancer Centre, Belfast City Hospital, Belfast, Northern
23 19 Ireland, UK

24 20 8. Northern Centre for Cancer Care, Freeman Hospital, Newcastle-upon-Tyne, UK

25 21 9. Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK

26 22 10. Velindre Cancer Centre, Cardiff University, Cardiff, UK

27 23 Corresponding authors:

28 24 1. Emma Clark:

29 25 • e-mail: emma.clark@ncl.ac.uk

30 26 • Phone: 0191 208 4456

31 27 2. Rakesh Heer:

32 28 • e-mail: rakesh.heer@ncl.ac.uk

33 29 • Phone: 0191 208 4300

34 30 Key Words:

- 35 31 • Prostate Disease
36 32 • Protocols and guidelines
37 33 • Adult Oncology
38 34 • Urological tumours
39 35 • Cell biology

40 36 This study opened to recruitment on the 09/07/2019 with the first patient consented
41 37 29/07/2019 and is expected to report in 18 months. This protocol is the current approved
42 38 VARIANT protocol Version 2.0 8th March 2019

43 39
44 40
45 41
46 42
47 43
48 44
49 45
50 46
51 47
52 48
53 49
54 50
55 51
56 52
57 53
58 54
59 55
60 56
1

39 **Abstract**

40 **Introduction:**

41 Prostate Cancer is the most common male cancer with 1 in 4 developing non-curable metastatic
42 disease. Initial treatment responses to hormonal therapies are transient and further management
43 options lie between [1] further hormone therapy or [2] a non-hormonal approach involving
44 additional chemotherapy or molecular radiotherapy (radium-223). There is no clear rationale
45 for choosing between these mechanistically different treatment approaches. The biology of
46 hormone resistance is driven through abnormal androgen receptor activity and we can assay
47 this through a blood test measuring androgen receptor variant 7 (AR-V7) expression in
48 circulating tumour cells (CTCs). Despite increasing evidence supporting AR-V7's role as a
49 prognostic marker, the clinical utility of such measures remains unknown in helping
50 personalise treatment decisions.

51 **Methods and Design:**

52 The VARIANT feasibility trial is a pragmatic design, to be run over 18 months with
53 participants randomised into the intervention arm receiving biomarker (AR-V7) guided clinical
54 treatment and participants randomised into the control arm with conventional standard
55 management (no biomarker guidance). AR-V7 positive participants (likely to be insensitive to
56 further hormone treatment) will receive chemotherapy or in other cases radium-223 (where
57 routinely available). Seventy male ≥ 18 years old participants with metastatic castrate resistant
58 prostate cancer clinically indicated to proceed to further hormone therapy or chemotherapy,
59 will be recruited from three National Health Service (NHS) Trusts based in England, Scotland
60 and Wales. The feasibility primary outcome is willingness of patients to be randomised and
61 clinicians to recruit to a biomarker-based treatment strategy, with trial data informing the basis
62 of a definitive and appropriately powered randomised control trial (RCT).

63 **Ethics and Dissemination:**

64 Formal ethics review was undertaken with a favourable opinion, through Wales NRES
65 Committee 2 18/WA/0419. Findings to be disseminated through patient and professional
66 organisations that have expressed their support, media outlets and peer-reviewed journal
67 publication.

68 **Article Summary**

69 **Strengths and limitations of this study:**

- 70 • **Focuses on a priority area of need in advanced prostate cancer clinical practice.**
- 71 • **To date, the feasibility of delivering a randomised biomarker guided-treatment**
72 **trial in prostate cancer to formally assess clinical utility is not established and will**
73 **be addressed in this study.**
- 74 • **As a feasibility study, the planned sample size (70 participants) does not have**
75 **sufficient power or precision to compare the 'event' rate between treatment arms,**
76 **but will allow informed planning for a definitive randomised controlled trial with**
77 **prominent clinicians from non-recruiting centres involved in feasibility, to aid**
78 **with follow-on trial.**

- 79 • **Emerging evidence points to additional Androgen Receptor (AR) biology driving**
80 **hormone resistance, such as other variant expression and mutations – these along**
81 **with alternative biomarkers can be explored in the associated biobanked samples**
82 **(including cell free tumour DNA).**
- 83 • **Strong patient and public involvement to inform study design with a clear**
84 **commitment to informing participants of project outcomes setting a clear new**
85 **gold standard for PPI.**

86 **INTRODUCTION**

87 **Background**

88 Prostate cancer (PC) is the most common male cancer in the UK and the second highest cause
89 of male cancer death(1). In large part, PC is a slowly progressive disease and when detected at
90 an early stage is managed by active surveillance, surgery or radiotherapy. However, 25% of
91 patients will present with, or will progress to, advanced metastatic PC(2,3). Metastatic PC is
92 incurable, with less than one third of patients surviving more than 5 years(1).

93 Medical castration (commonly referred to as hormonal treatment or androgen deprivation
94 therapy (ADT)), blocks production of the hormone testosterone and/or targets the androgen
95 receptor (AR) signalling axis that drives cancer cell growth. Although a good response to
96 hormonal treatment seen often initially, disease progression to a lethal metastatic Castration-
97 Resistant Prostate Cancer (mCRPC) is common(4). Clinical trials have shown that the addition
98 of chemotherapy (docetaxel) or other hormonal approaches (abiraterone acetate or
99 enzalutamide) to initial hormonal therapy have led to a substantial improvement (i.e. delay) in
100 time to the development of mCRPC and overall survival (OS)(5-9). Furthermore, promising
101 recent evidence from randomised trials of androgen-receptor axis-targeted drugs (ARATs)
102 have shown addition of Apalutamide (an inhibitor of the ligand-binding domain of the AR),
103 alongside hormone therapy results in longer overall survival and radiographic progression free
104 survival compared to placebo(10). However despite these rapid advances, mCRPC typically
105 manifests within 3 years and is uniformly fatal(11-13).

106 **Treatment management for mCRPC**

107 Management pathways for mCRPC are still evolving in response to emerging new treatments
108 however, it broadly follows one of two standard care approaches(14); [1] further hormonal
109 treatment such as abiraterone or enzalutamide or [2] ‘non-hormonal’ treatment, typically
110 chemotherapy or molecular radiotherapy (radium 223) (where available). There is no clear
111 biological rationale for choosing between these mechanistically different treatment approaches.
112 Suitable patients for this study can receive both approaches in a sequential manner if one is
113 failing. Patients and clinicians often prefer hormonal treatment, being less toxic and easier to
114 manage, however, only 30-50% of men respond well, with the remainder demonstrating a poor
115 or an equivocal response(15,16). As many patients will not respond to either treatment
116 approach, there are considerable costs from our current management pathways, both in terms
117 of patient experience and outcomes (side effects and disease progression) and economic costs
118 to the NHS (large burden of expensive treatments for the commonest male cancer).
119 Personalised management pathways are urgently needed.

120 **Biology of the Androgen Receptor (AR selective treatment pressure)**

3

1
2
3 121 A breakthrough in understanding the biology of PC revealed that hormonal treatments generate
4 122 a selective pressure at the cellular level inducing complex molecular mechanisms characterised
5 123 by an adaptation of the androgen-AR signalling axis. This results in tumour resistance mediated
6 124 by the induced expression of alternative types of androgen receptor. These AR mRNA splice
7 125 variants lack the important hormone-binding domain, resulting in a constitutively active
8 126 cellular receptor, despite castration. The most widely studied variant is AR-V7(17,18). AR-V7
9 127 activity is not affected by 'hormonal treatment' such as enzalutamide and abiraterone that target
10 128 the hormone-binding domain, potentially rendering these treatments ineffective in men with
11 129 AR-V7(19-21). A surge in ARATs available for clinical use (e.g. Apalutamide and
12 130 Darolutamide) will most likely enhance this burden (although of note, evidence demonstrating
13 131 reduced effectiveness of these specific treatment in men who are positive for AR-V7 or other
14 132 variant splice forms including AR point mutations, have not been published to date).

19 133 **Rationale**

20 134 Published clinical data demonstrates a strong link between AR-V7 expression and mCRPC
21 135 progression and highlights the potential for AR-V7 to be utilised as a treatment stratification
22 136 biomarker to identify those men likely to be sensitive to further hormonal treatment (AR-V7-
23 137 ve patients) and avoid futile treatments in those predicted to be insensitive (AR-V7+ve
24 138 patients)(21-29). Notably AR-V7 positivity is not associated with insensitivity to taxane
25 139 chemotherapy treatment (relative reduction in risk of death of 76% maintained with
26 140 chemotherapy, hazard ratio: 0.24; 95% CI, 0.10-0.57; P = 0.035)(27,30) and data from the
27 141 recent PROPHECY trial reports on the prognostic value of the AR-V7 biomarker (prospective
28 142 observational cohort of poor prognosis patients with advanced prostate cancer who receive
29 143 abiraterone or enzalutamide treatment)(30). The commercially available AdnaTest
30 144 ProstateCancerPanel AR V7 assay (Qiagen®) detects AR-V7 mRNA expression in circulating
31 145 tumour cells (CTCs) in whole blood and has been independently and robustly clinically
32 146 validated in terms of reproducibility and comparisons of sensitivity and specificity with other
33 147 AR-V7 detection platforms(31-33). However to date, there have been no formal measures of
34 148 the clinical utility of AR-V7 as a predictive biomarker

40 149 **Evidence gap**

41 150 Encouragingly, a cost saving analysis of performing ProstateAdnaTest AR-V7 biomarker
42 151 testing in mCRPC demonstrated use of the biomarker would result in a substantial cost saving
43 152 as long as the true prevalence of AR-V7 was >5% (well below the accepted prevalence rate of
44 153 30%)(34). However, formal cost effectiveness analyses based on incremental cost-
45 154 effectiveness ratio (ICER) (cost per quality-adjusted life year gained) and assessing prevalence
46 155 rates of this biomarker have yet to be carried out.

47 156 The National Comprehensive Cancer Network Task Force(35) and CRUK consensus statement
48 157 on biomarker roadmap for cancer studies(36), have highlighted the key recommendations for
49 158 accelerating a tumour biomarker into clinical practice by sequentially demonstrating evidence
50 159 for; (1) analytic reproducibility; (2) clinical validity and; (3) clinical utility. Previous clinical
51 160 studies on AR-V7 testing focused on retrospective or prospective cohort analyses of associated
52 161 AR-V7 expression distinguishing subgroups with different clinical outcomes with hormonal
53 162 treatment in men with metastatic PC(37-40). However, the highest level of assessment of
54 163 clinical worth in improving patient outcomes (clinical utility) remains lacking. We have paid

1
2
3 164 particular focus to address clinical utility evidence gaps in the VARIANT trial using published
4 165 levels of evidence standards for assessing biomarkers to inform study design(41-42). We aim
5 166 to demonstrate improvement in patient outcome sufficiently to justify AR-V7 biomarker
6 167 incorporation into routine clinical care (including feasibility of collecting quality of life
7 168 measures for a future health economic evaluation).

10 169 **Emerging treatment landscape**

11
12 170 The treatment landscape of hormone sensitive (PC) is evolving, altering treatment pathways
13 171 for mCRPC. Recent data from the USA based PROPHECY trial reporting on a prospective
14 172 observational cohort showed mRNA AR-V7 (modified Qiagen ProstateCancerAdnaTest,
15 173 Baltimore, MD) and protein AR-V7 (Epic nuclear-specific, San Diego) biomarker positivity
16 174 associated with worse progression free survival (PFS) and overall survival (OS) in poor
17 175 prognosis patients with advanced prostate cancer who receive abiraterone or enzalutamide
18 176 treatment(30). Criticisms of the study included lack of testing with alternative treatment such
19 177 as chemotherapy (which we have addressed in this study) and pre-selection of high risk CRPC
20 178 patients (i.e. those with poor prognosis), ultimately generating results that cannot be
21 179 extrapolated over the overall CRPC population(43-46). Of note, lower AR-V7 prevalence was
22 180 reported in the overall CRPC population in the ARMOR3-SV phase III clinical trial which
23 181 employed the Adnatest ProstateCancerSelect and Detect CTC assay (Qiagen®) to assess AR-
24 182 V7 mRNA expression, where only 8% of men were AR-V7 positive (95% CI 6-10)(47,48).
25 183 During reviewing of this protocol, results of the CARD trial (Cabazitaxel versus Abiraterone
26 184 or Enzalutamide in Metastatic Prostate Cancer) were published showing median overall
27 185 survival was 13.6 months with cabazitaxel and 11.0 months with androgen signalling targeted
28 186 inhibitors (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P=0.008). CARD investigators
29 187 plan to analyse CTCs for AR-V7 in order to determine the prognostic and predictive value of
30 188 CTC-derived AR-V7 detection, further contributing important findings from this evolving
31 189 treatment landscape(49).

32
33 190 We argue irrespective of the evolving treatment landscape, the opportunity to generate
34 191 feasibility data for a biological (biomarker) informed approach to treatment selection over
35 192 standard care protocol-based approaches, tests a highly relevant clinical question in these high
36 193 risk CRPC patients (i.e. those who have more to loose from pursuing a 'try and see' approach).
37 194 This would provide an appealing long-term strategy (for patients and service providers) to
38 195 ultimately improve on clinical outcome (specifically for a clinical subgroup of poor prognosis
39 196 patients, identifying those likely to be sensitive to further hormonal treatment and avoid futile
40 197 treatments in those that are predicted to be insensitive).

41 198 **Main Aim of Study**

42 199 To determine the feasibility of conducting a definitive randomised control trial to evaluate the
43 200 clinical utility of an AR-V7 blood biomarker assay in personalising treatment for men with
44 201 mCRPC in UK NHS clinical practice.

45 202 **Objectives**

46 203 Feasibility study

1
2
3 204 **Primary:**

- 4 205 1. To establish if it is feasible to conduct a definitive trial comparing AR-V7 biomarker-
5 206 driven management with the current standard care in patients with mCRPC.

7
8 207 **Secondary Objectives:**

- 9
10 208 2. To estimate AR-V7 biomarker prevalence in the trial population to inform sample size
11 209 calculations for a definitive randomised control trial.
12
13 210 3. To assess recruitment, compliance and retention rates
14 211 4. To confirm outcome measures for a future definitive trial and establish trial data
15 212 response rates, variability, and data quality.
16 213 5. To establish a blood sample biorepository to include baseline, 12 and 24 week blood
17 214 samples for future translational studies.

18 215 **Exploratory objectives:**

- 19 216 6. To establish a complete serial blood tissue archive to include potential measures of cell
20 217 free DNA and additional AR-Variants in CTCs and cfDNA biomarker measures (such
21 218 as AR mutations, other AR splice forms and AR amplification and other mutations such
22 219 as PTEN/p53/MYC gain/RB1 loss/MET gain and further molecular pathways yet to be
23 220 defined), to complement AR-V7 reads, depending upon the ultimate biomarker
24 221 performance characteristic established in this trial population. Blood will be collected,
25 222 processed and archived at 0 weeks (baseline), 12 weeks and 24 weeks following the
26 223 first treatment.
27 224 7. To explore thresholds of the magnitude of AR-V7 positivity to investigate relationships
28 225 with outcomes and to estimate AR-V7 positivity rate assumptions regarding a cut-off
29 226 point.
30 227 8. To undertake cross site validation of biomarker reads between two GCP laboratories
31 228 (Newcastle University and Cardiff University).
32 229

33 230 **METHODS AND ANALYSIS**

34 231 **Study design**

35 232 This feasibility study is a multi-centre, two-arm, randomised control trial (RCT). All patients
36 233 who consent to take part in the trial and who are eligible, will have a blood test to assess
37 234 prevalence rate of the AR-V7 biomarker. Participants will be randomised in the ratio 1:1 to
38 235 receive personalised standard treatment (intervention) guided by AR-V7 biomarker status or
39 236 standard care (control) without biomarker guided treatment. Those in the control group will
40 237 not receive blood biomarker test results.

41 238 The treatment for each patient is expected to be dependent on various factors (e.g. clinician
42 239 choice, patient choice, previous treatments, co-morbidities, concomitant medication and
43 240 pattern of disease) as well as randomised allocation and AR-V7 status in the personalised
44 241 treatment arm. All treatments are part of standard care for these participants. Treatment options
45 242 for participants randomised to the personalised standard treatment arm will be recommended,
46 243 but not mandated within this feasibility trial, with reasons for not following the

244 recommendation recorded and reported as outcome. A CONSORT diagram of study protocol
245 (version 2.0 8th March 2019) is shown in figure 1.

246 **Study Setting**

247 Seventy patients with mCRPC who require a change in treatment will be recruited in three
248 secondary care NHS Trusts in the UK spread across England (The Newcastle upon Tyne
249 Hospitals NHS Foundation Trust), Scotland (NHS Greater Glasgow and Clyde) and Wales
250 (Velindre University NHS Trust). We aim to recruit mCRPC patients with a predicted poor
251 overall survival. We anticipate this group of mCRPC patients have the most to gain from a
252 biological-based treatment approach as their disease is more likely to progress during a period
253 of treatment with an inactive agent. Multivariate analysis from the metastatic population of
254 STAMPEDE(50) has shown that worse overall survival was seen in men with the following
255 features: presence of bone metastases (regardless of soft tissue metastases), worse WHO
256 performance status (0 vs 1 or 2), higher (or unknown) initial Gleason sum score category (≥ 8
257 vs ≤ 7), and younger age at randomisation < 60 yrs. Poorer failure free survival (but not overall
258 survival was additionally seen in men with worse primary tumour stage and higher PSA level
259 before starting ADT. There is overlap between these poor prognostic features and factors
260 associated with a high likelihood of harbouring AR-V7+ve CTCs(33, 40, 51).

261 **Eligibility Criteria**

262 Patients will be aged ≥ 18 years old with metastatic castrate resistant prostate cancer (high risk
263 features) clinically indicated to proceed to further hormone therapy or chemotherapy and fulfil
264 all of the following criteria:

- 265 1. Histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
- 266 2. Radiographic and/or histological and/or cytological evidence of metastatic disease.
- 267 3. Castrate levels of testosterone and documented ongoing medical or surgical castration.
268 Testosterone level ≤ 50 ng/dl /1.73 nmol/L and maintaining on androgen suppression
269 therapy.
- 270 4. Disease progression since the last change in therapy defined by one or more of the
271 following: (i) PSA progression as defined by the prostate cancer working group 3
272 (PCWG3) criteria ≥ 2 ng/ml; (ii) bone disease progression as determined by the local
273 radiology/ multidisciplinary team; (iii) radiographic progression of nodal or visceral
274 metastases as determined by the local radiology/ multidisciplinary team.
- 275 5. Suitable for treatment with at least one novel hormonal treatment (with available
276 treatments abiraterone acetate or enzalutamide) and one non-hormonal therapy (with
277 available treatments docetaxel, cabazitaxel or radium-223).
- 278 6. At least two high risk features: (i) age < 60 years at time of diagnosis of metastatic
279 disease; (ii) bone metastases present at time of initial metastatic prostate cancer
280 diagnosis (although not mandated, it is considered good clinical practice to have up to
281 date imaging within 8 weeks); (iii) Gleason grade group 4 or 5 (Gleason score 8 to 10);
282 (iv) presence of visceral metastases (e.g. liver or lung) at any time point. This does not
283 include lymph node metastases; (v) PSA doubling time < 3 months; (vi) elevated
284 alkaline phosphatase above institutional upper limit of normal; (vii) ECOG

- 1
2
3 285 Performance Status worse than or equal to 1; (viii) previous treatment for castration
4 286 resistant prostate cancer with docetaxel chemotherapy; (ix) previous treatment for
5 287 castration resistant prostate cancer with abiraterone and/or enzalutamide or equivalent
6 288 agent.
7
8 289 7. Estimated life expectancy > 6 months.
9
10 290 8. Provision of written informed consent, including consent for bio-banking of blood
11 291 samples.

12
13 292 Exclusion Criteria applied in the VARIANT trial are:

- 14 293 1. Histological variants of prostate cancers with small cell or neuroendocrine features.
15 294 2. Prior or current malignancy (except adenocarcinoma of the prostate) with an estimated
16 295 $\geq 30\%$ chance of relapse/progression within next 2 years.
17 296 3. Previously identified brain metastases or spinal cord compression unless treated with
18 297 full functional recovery.
19 298 4. Administration of an investigational agent within 30 days of first dose of trial
20 299 medication.

24 25 300 **Randomisation**

26 301 Patients will be randomised to receive either personalised standard treatment (guided by AR-
27 302 V7 biomarker status) or standard care (not guided by biomarker status) on a 1:1 basis using a
28 303 method of random permuted blocks of concealed variable block size and stratified by site.

30 304 **Study Intervention**

31 305 This three-centre randomised feasibility study incorporates a control and an intervention arm.
32 306 All patients will undergo AR-V7 biomarker assessment with results only made known to the
33 307 patients and clinical team in the intervention arm.

35 308 **Intervention arm**

36 309 Treatment will be given as per standard care with recommendations guided by biomarker
37 310 status; (1) If the participant is found to be AR-V7 positive, then non-hormonal treatment is
38 311 recommended (docetaxel chemotherapy, cabazitaxel chemotherapy or radium-223 therapy) or
39 312 (2) if the participant is found to be AR-V7 negative, then next generation hormonal treatment
40 313 is recommended (either enzalutamide or abiraterone).

41 314 The results of the AR-V7 biomarker assessment will be provided securely to the clinical team
42 315 to enable tailored treatments based on AR-V7 expression from the biomarker result. Where a
43 316 decision is made that the participant will receive a non recommended therapy (either by the
44 317 clinician or patient) this therapy, and the reasons for giving this, will be documented.

46 318 **Control arm**

47 319 Participants with their clinical care team will make an informed and preference-based decision
48 320 to receive standard care, including either next generation hormone treatments abiraterone or
49 321 enzalutamide or non-hormonal approaches including docetaxel or cabazitaxel chemotherapy
50 322 or radium-223. Details of all treatment administered, including doses, will be recorded as part
51 323 of the trial.

52 324 The research team at sites will not receive the participants AR-V7 biomarker results.

54 325 **Outcome Measures**

55 326 Standardised clinical assessment tools used in monitoring CRPC disease and progression on
56 327 treatment will be reported (listed in box 1). Primary outcome measures are related to feasibility
57 328 (recruitment, retention and adherence) and will report the following;

- 1
2
3 329 (1) the proportion of prostate cancer patients identified through clinics who meet the eligibility
4 330 criteria;
5
6 331 (2) the number of patients accrued per site per month over the course of the trial;
7 332 (3) baseline prevalence of AR-V7 expression in the participant cohort (this will be presented
8 333 as a crude percentage of AR-V7 positivity of total participants, and in each arm);
9
10 334 (4) the willingness of patients to be randomised (defined as the proportion of patients
11 335 consenting to be randomised from all eligible patients approached about the study);
12 336 (5) compliance rate (this will be defined as the number of patients who start randomised
13 337 treatment as a proportion of the number randomised);
14
15 338 (6) the proportion of patients who: start AR-V7 recommended treatment; start treatment other
16 339 than the recommended treatment; change treatment before disease progression; or withdraw.
17 340 (This measure will capture information regarding patients who choose not to take
18 341 recommended treatment because of strong preferences and patients who progress rapidly while
19 342 waiting for treatment with a change in eligibility for treatment options).
20
21 343 (7) the proportion of trial participants with assessable blood samples for biomarker status
22 344 (which would affect treatment targeting);
23
24 345 (8) the median time from the blood sample being drawn to; (i) AR-V7 result being sent back
25 346 to the site and (ii) patient starting treatment (and compared with standard of care treatment).
26
27 347 (9) the proportion of randomised patients for whom data is collected on each clinical and health
28 348 economic outcome at baseline, 12 and 24 weeks.
29
30 349

Box 1 Standardised Clinical Assessment Tools

Clinical Outcome Measures:

- 31
32
33
34 (1) Time to PSA progression; (i) Confirmed rising PSA more than 12 weeks after
35 randomisation. (*Where there has been a decline in PSA from baseline, progression will be a*
36 *25% or greater increase, and an absolute increase of at least 2ng/mL, from the nadir, which*
37 *is confirmed by a second value obtained 3 or more weeks later. Where no decline from*
38 *baseline is documented, progression must be a 25% or greater increase from the baseline*
39 *value along with an increase in absolute value of 2 ng/mL or more. In all cases, the initial*
40 *rise in PSA must occur after a minimum of 12 weeks from randomisation).*
- 41
42
43 (2) Clinical progression and survival within 6-months; (i) Number of patients who have
44 progressed clinically at 6-months (includes change of systemic anti-cancer therapy and death
45 from PC); (ii) Cancer specific survival at 6-months; and (iii) overall survival at 6-months.
46
47 (3) Quality of life for patients with cancer (EORTC QLQ-C30).
48
49 (4) Additional quality of life items patients with prostate cancer (EORTC QLQ-PR25).
50
51 (5) Participant costs questionnaire (Use of Health Services Questionnaire).

51 350 Further information on recruitment, screening, the patient consent procedure and informed
52 351 consent literature can be found in the supplementary section.

352 **Data collection**

53
54
55
56 353 Table 1 shows a trial schedule of events. A more detailed description of all data collection
57 354 including a data management plan, can be found in the supplementary section. In summary, in
58 355 addition to collecting standard care assessment of disease status data from patients in the
59
60 9

356 intervention and control arms, trial specific questionnaire assessment (EORTC QLQ-C30
 357 Quality of Life of Cancer Patients, EORTC QLQ-PR25 Quality of Life Prostate Cancer
 358 Module) will take place at the baseline, 12 and 24 week visit.

Procedure	Screening	VISIT 1 Consent/ Baseline	VISIT 2 12 weeks (+/- 2 weeks)	VISIT 3 24 weeks (+/- 2 weeks)
Medical History and Demographics	X			
Record results of standard care PSA test	X	X	X	X
Eligibility Assessment	X ^a	X ^a		
Patient Information Sheet	X			
Informed consent		X		
Testosterone if no previous confirmation		X ^b		
Confirmation of eligibility		X ^a		
Randomisation		X		
Access to standard of care haemoglobin and biochemistry results		X		
Blood sample collection and shipment for CTC/ctDNA blood assessment and AR-V7 analysis (analysed at Newcastle University Central Analysis Lab)		X	X	X
CTC blood sample collection and shipment for cross site validation ^c (analysed at Cardiff University Central Analysis Lab)		X ^c		
EORTC QLQ-C30/PR25 Questionnaires		X		X
AR-V7 blood test result feedback to patient ^d		X ^d		
Use of Health Services Questionnaire				X

Anti-cancer therapy review			X	X
Clinical assessment of disease status			X	X

359 Table 1. Trial Schedule of Events

360 a = Eligibility assessment performed against trial eligibility criteria in screening, patients likely
 361 to be eligible will be given a VARIANT Information Sheet and trial information. Eligibility
 362 will be confirmed by an Investigator (medically qualified doctor) after patients have provided
 363 written informed consent and before randomisation.

364 b = in those cases where there is no previous confirmation of castrate levels of testosterone
 365 only. These patients will not be randomised until castration is confirmed and the patient is
 366 documented as eligible.

367 c = for selected patients only (confirmed at randomisation), for cross site validation of AR-V7
 368 status

369 d = for patients randomised to the personalised standard treatment arm (guided by AR-V7
 370 biomarker) only.

371 **AR-V7 biomarker measure**

372 A validated two-centre pipeline (consisting of preanalytical, analytical and postanalytical
 373 phases) to measure AR-V7 biomarker using the commercially available AdnaTest
 374 ProstateCancerPanel AR-V7 circulating tumour cell (CTC) quantitative RT-PCR (RT-qPCR)
 375 assay (Qiagen®) (intended for molecular biology applications), has been set up according to
 376 assay manufacturers recommendations, analytical methods and sponsor agreed SOP's.
 377 Following biomarker data analysis and data verification, for participants randomised to the
 378 intervention standard treatment arm (AR-V7 biomarker guided), the baseline biomarker result
 379 and biomarker treatment recommendation will be sent securely within 10 working days to the
 380 local PI and delegated research staff. Further information on the specifics of AR-V7 biomarker
 381 driven personalised treatment (sample receipt, processing, analysis and reporting of read-out)
 382 can be found in the supplementary section.

383 **Data Analysis Plan**

384 Analyses will be conducted on an intention-to-treat basis, with sensitivity analyses used to
 385 investigate the impact of non-compliance to allocated arm. Given the feasibility status of this
 386 study, all statistical analyses will be descriptive. The majority of the outcome data will be
 387 presented in simple descriptive tables presenting percentages, means and standard deviations
 388 or 5-number summary (as appropriate), for each arm of the study. Analysis of clinical and
 389 biomarker measures will be assessed by; (1) clinical progression and survival within 6-months;
 390 (2) PSA response/progression (confirmed rising PSA more than 12 weeks after randomisation);
 391 (3) clinical progression and survival (overall and cancer specific) within 6-months (includes
 392 change of cancer therapy for progression); and (4) survival (overall and progression free)

393 estimates will be derived using the Kaplan Meier method and presented as 6-month rates with
394 confidence intervals. The relationship between survival estimates and continuous AR-V7
395 biomarker expression will be modelled considering non-linear transformations in a univariate
396 Cox model, or parametric alternative, presented as parameter estimates (HR) with confidence
397 intervals.

398 Compliance with quality of life and health economic measures will be assessed by; (1) number
399 of patients completing measures as a proportion of the number randomised; (2) degree of
400 completeness of each domain of the EORTC QoL and economic questionnaire measures. These
401 scores will be presented graphically and with numeric descriptive statistics..

402 **Study statistical size calculations**

403 This trial is designed as feasibility trial according to definition of Eldridge *et al.*(52). Feasibility
404 includes the deliverability of the intervention and in this case, assessment of the frequency of
405 the positive assay measurements (predicted at approximately 30%). It has been recommended
406 that data in an external pilot trial is collected on a minimum of 60 patients per arm to estimate
407 the 'event' rate(53). However, we plan to calculate a pooled estimate of overall recruitment
408 rate, and overall biomarker prevalence rate, and will recruit 70 patients in total to allow for
409 attrition.

410 The performance of potential outcome measures for a definitive trial will be assessed by
411 estimating data completeness of the instruments and any potential bias in the completion of
412 follow-up data. This information will be used to inform the design, choice of outcomes,
413 necessary sample size and approach to the analysis, of a future definitive trial.

414 **Safety Reporting**

415 This is a low risk trial and no specific safety reporting is required. Should an Investigator have
416 any concern regarding participant safety as an outcome of their participation in the trial, they
417 will contact the Trial Management Group (TMG) and Chief Investigator as soon as possible.
418 The Trial Oversight Committee (TOC) will monitor concerns as required.

419 **Trial Conduct and Governance**

420 The trial will be conducted in accordance with the UK Policy Framework for Health and Social
421 Care and, as applicable, the Guidelines for Good Clinical Practice. The TMG is responsible for
422 the day-to-day management of the trial, overseeing all aspects of the conduct of trial to ensure
423 that the protocol is adhered to and take appropriate actions to ensure patient and data safety.
424 The TOC will review trial conduct and accumulating clinical trial data and provide overall
425 supervision for the trial on behalf of the Sponsor and the Funder. The constitution of the TMG
426 and TOC including roles and responsibilities delegation for this trial can be found in the
427 supplementary section. Aggregated data will be analysed by the Trial Statisticians and reported
428 to an external independent TOC at least annually.

429 **Public and Patient Involvement**

430 The design, planning and management of this trial has been supported by two prostate cancer
431 patient representatives (co-applicant on the funding grant and TMG member). Both have
432 advocated the dissemination of trial findings to patients and ensured that the public was
433 adequately considered during trial design. PPI has been embedded into the study, with the
434 patient's voice a strong theme to inform and influence the on-going research and development
435 of participant information resources in collaboration with the 'Cancer Perspectives' patient
436 representative group (Newcastle upon Tyne Hospitals NHS Foundation Trust). A strong
437 commitment is to inform the participants of the outcome of this project, a clear new gold
438 standard for PPI.

439 **Ethics and dissemination**

440 Favourable ethical opinion has been obtained from the Wales National Research Ethics Service
441 (NRES) Committee 2 18/WA/0419. All parties will conduct the trial in accordance with this
442 ethical opinion. No amendment to protocol will be made without consideration and approval
443 by the Trial Management Committee.

444 Feasibility data will be published as a peer-reviewed article and if successful, these findings
445 will contribute to gaining further funding for a HTA full trial. In addition, assessing clinical
446 data and blood derivatives from the participant cohort will provide valuable material
447 (circulating tumour cells CTCs, transcript & plasma ctDNA), to validate translational studies
448 of other AR aberrations and hormone targeting resistance pathways (or the emergence of
449 biomarkers for chemo-sensitivity), to inform and contribute further to the rapidly evolving
450 treatment developments for CRPC. Participants will remain anonymised in all publications.

451 We will also utilise dissemination through patient and professional organisations that have
452 expressed their support for this trial (PCF, CRUK, NCRI Prostate CSG and BAUS) and through
453 media outlets including web resources, lay press, academic national and international
454 conferences and peer-reviewed journal publication.

455 Trial registration number: ISRCTN10246848

456 **Figure legends**

457 Figure 1 VARIANT trial consort diagram. Planned flow of participants throughout the
458 VARIANT study. mCRPC, Metastatic Castrate Resistant Prostate Cancer; PSA, Prostate
459 Specific Antigen; EORTC-QLQ-C30/PR25, European Organisation for Research and
460 Treatment of Cancer Quality of Life Questionnaire; AR-V7, Androgen Receptor Variant 7.

461 **References**

462 1. Cancer Research UK (CRUK). Prostate Cancer Statistics. Electronic citation. [accessed 2019
463 August]. Available from: [https://www.cancerresearchuk.org/health-professional/cancer-](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer)
464 [statistics/statistics-by-cancer-type/prostate-cancer](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer).

- 1
2
3 466 2. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in
4 467 overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-
5 468 year period. *Cancer*. 2014;120(6):818-23.
6 469
- 7 470 3. Public Health England. Cancer Information Tools. Electronic citation. [accessed 2019 Aug].
8 471 Available from: http://www.ncin.org.uk/cancer_information_tools .
9 472
- 10 473 4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. *Nat*
11 474 *Rev Cancer*. 2001;1(1):34-45.
12 475
- 13 476 5. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition
14 477 of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer
15 478 (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised
16 479 controlled trial. *Lancet*. 2016;387(10024):1163-77
17 480
- 18 481 6. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al.
19 482 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term
20 483 Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. *J Clin Oncol*.
21 484 2018;36(11):1080-87
22 485
- 23 486 7. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al.
24 487 Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *N Engl J*
25 488 *Med*. 2017;377(4):338-351
26 489
- 27 490 8. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al.
28 491 Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J*
29 492 *Med*. 2017;377(4):352-360
30 493
- 31 494 9. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide
32 495 with Standard First-Line Therapy in Metastatic Prostate Cancer. *N Engl J Med*.
33 496 2019;381(2):121-31.
34 497
- 35 498 10. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al.
36 499 Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*.
37 500 2019;381(1):13-24.
38 501
- 39 502 11. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, et al. Efficacy
40 503 of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association
41 504 between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration
42 505 of ADT effect. *Cancer*. 2008;112(6):1247-53.
43 506
- 44 507 12. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et
45 508 al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *N Engl J*
46 509 *Med*. 1998;339(15):1036-42.
47 510
- 48 511 13. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A
49 512 controlled trial of leuprolide with and without flutamide in prostatic carcinoma. *N Engl J Med*.
50 513 1989;321(7):419-24.
51 514

- 1
2
3 515 14. ASCO. Practice Guidelines. [https://wwwascoorg/practice-guidelines/qualityguidelines/
4 516 guidelines/genitourinary-cancer](https://wwwascoorg/practice-guidelines/qualityguidelines/guidelines/genitourinary-cancer). Accessed 13/10/2016.
5 517
- 6 518 15. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone
7 519 in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*. 2013;368(2):138-
8 520 48.
9 521
- 10 522 16. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival
11 523 with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*. 2012;367(13):1187-
12 524 97.
13 525
- 14 526 17. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. *Endocr Relat
15 527 Cancer*. 2011;18(5):R183-96.
16 528
- 17 529 18. Luo J. Development of AR-V7 as a putative treatment selection marker for metastatic
18 530 castration-resistant prostate cancer. *Asian J Androl*. 2016;18(4):580-5.
19 531
- 20 532 19. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance
21 533 of androgen receptor variants in castration resistant prostate cancer. *Endocr Relat Cancer*.
22 534 2014;21(4):T87-T103.
23 535
- 24 536 20. Beltran H, Antonarakis ES, Morris MJ, Attard G. Emerging Molecular Biomarkers in
25 537 Advanced Prostate Cancer: Translation to the Clinic. *Am Soc Clin Oncol Educ Book*.
26 538 2016;35:131-41.
27 539
- 28 540 21. Maughan BL, Antonarakis ES. Clinical Relevance of Androgen Receptor Splice Variants
29 541 in Castration-Resistant Prostate Cancer. *Curr Treat Options Oncol*. 2015;16(12):57.
30 542
- 31 543 22. Daniel M, Dehm SM. Lessons from tissue compartment-specific analysis of androgen
32 544 receptor alterations in prostate cancer. *J Steroid Biochem Mol Biol*. 2016.
33 545
- 34 546 23. Stone L. Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker. *Nat Rev
35 547 Urol*. 2016;13(8):433.
36 548
- 37 549 24. Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen
38 550 deprivation therapy in prostate cancer. *Oncotarget*. 2016.
39 551
- 40 552 25. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-
41 553 based analysis of AR-V7 in men with advanced prostate cancer. *Ann Oncol*. 2015;26(9):1859-
42 554 65.
43 555
- 44 556 26. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, et al. Detecting
45 557 predictive androgen receptor modifications in circulating prostate cancer cells. *Oncotarget*.
46 558 2015.
47 559
- 48 560 27. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7
49 561 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival
50 562 in Castration-Resistant Prostate Cancer. *JAMA Oncol*. 2016.
51 563
52
53
54
55
56
57
58
59
60

- 1
2
3 564 28. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent
4 565 androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory
5 566 prostate cancer. *Cancer Res.* 2009;69(1):16-22.
6 567
- 7 568 29. Antonarakis ES, Lu C, Wang H, Lubner B, Nakazawa M, Roeser JC, et al. AR-V7 and
8 569 resistance to enzalutamide and abiraterone in prostate cancer. *N Engl J Med.*
9 570 2014;371(11):1028-38.
10 571
- 11 572 30. Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, et al.
12 573 Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone
13 574 Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY
14 575 Study. *J Clin Oncol.* 2019;37(13):1120-9.
15 576
- 16 577 31. Antonarakis ES, Lu C, Lubner B, Wang H, Chen Y, Nakazawa M, et al. Androgen Receptor
17 578 Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-
18 579 Resistant Prostate Cancer. *JAMA Oncol.* 2015;1(5):582-91.
19 580
- 20 581 32. Todenhofer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kuhs U, et al.
21 582 Preliminary experience on the use of the Adnatest(R) system for detection of circulating tumor
22 583 cells in prostate cancer patients. *Anticancer Res.* 2012;32(8):3507-13.
23 584
- 24 585 33. Antonarakis ES, Lu C, Lubner B, Wang H, Chen Y, Zhu Y, et al. Clinical Significance of
25 586 Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with
26 587 Metastatic Castration-Resistance Prostate Cancer Treated with First- and Second-Line
27 588 Abiraterone and Enzalutamide. *J Clin Oncol.* 2017;35(19):2149-56
28 589
- 29 590 34. Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-savings analysis of
30 591 AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for
31 592 treatment with abiraterone or enzalutamide. *Prostate.* 2016.
32 593
- 33 594 35. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, et al. NCCN
34 595 Task Force report: Evaluating the clinical utility of tumor markers in oncology. *J Natl Compr*
35 596 *Canc Netw.* 2011;9 Suppl 5:S1-32; quiz S3.
36 597
- 37 598 36. O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, et al. Imaging
38 599 biomarker roadmap for cancer studies. *Nat Rev Clin Oncol.* 2017;14(3):169-86.
39 600
- 40 601 37. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, et al. Expression of
41 602 androgen receptor splice variants in prostate cancer bone metastases is associated with
42 603 castration-resistance and short survival. *PLoS One.* 2011;6(4)
43 604
- 44 605 38. Antonarakis ES. Predicting treatment response in castration-resistant prostate cancer: could
45 606 androgen receptor variant-7 hold the key? *Expert Rev Anticancer Ther.* 2015;15(2):143-5.
46 607
- 47 608 39. Antonarakis ES, Luo J. Prostate cancer: AR splice variant dimerization-clinical
48 609 implications. *Nat Rev Urol.* 2015;12(8):431-3
49 610
50 611

- 1
2
3 612 40. Sieuwerts AM, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort CM, Van M, et al.
4 613 An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7
5 614 mRNA Expression in Circulating Tumor Cells. *J Mol Diagn*. 2018;20(3):316-25.
6 615
- 7 616 41. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, et al. Tumor
8 617 marker utility grading system: a framework to evaluate clinical utility of tumor markers. *J Natl*
9 618 *Cancer Inst*. 1996;88(20):1456-66.
10 619
- 11 620 42. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and
12 621 predictive biomarkers. *J Natl Cancer Inst*. 2009;101(21):1446-52.
13 622
- 14 623 43. Sharp A, Porta N, Lambros MBK, Welti JC, Paschalis A, Raj GV, et al. Dissecting
15 624 Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced
16 625 Prostate Cancer. *J Clin Oncol*. 2019;37(24):2182-4.
17 626
- 18 627 44. De Laere B, Ost P, Gronberg H, Lindberg J. Has the PROPHECY of AR-V7 Been
19 628 Fulfilled? *J Clin Oncol*. 2019;37(24):2181-2.
20 629
- 21 630 45. Dirix L. Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With
22 631 Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study. *J Clin Oncol*.
23 632 2019;37(24):2180-1.
24 633
- 25 634 46. Armstrong AJ, Halabi S, Luo J, Nanus DM, Scher HI, Antonarakis ES, et al. Reply to L.
26 635 Dirix, B. De Laere et al, and A. Sharp et al. *J Clin Oncol*. 2019;37(24):2184-6
27 636
- 28 637 47. Attard G, Borre M, Gurney H, Loriot Y, Andresen C, Kalleda R, et al. ASCO 2017: Clinical
29 638 factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone vs
30 639 enzalutamide in men with AR-V7+ metastatic castration-resistant prostate cancer. Abstract
31 640 2017 ASCO Annual Meeting. June 2-6, 2017, Chicago.
32 641
- 33 642 48. Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein BA, Saad F, et al.
34 643 Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of
35 644 galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant
36 645 prostate cancer (mCRPC). *J Clin Oncol*. 2017;35:15_suppl, 5005-5005
37 646
- 38 647 49. de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, et al. Cabazitaxel
39 648 versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *N Engl J Med*. 2019: Sep
40 649 30.
41 650
- 42 651 50. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with
43 652 Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients
44 653 in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). *Eur Urol*.
45 654 2015;67(6):1028-38
46 655
- 47 656 51. Grafa R, Hullings M, Barnett E, Carbone E, Dittamore R, Howard S. Clinical Utility of the
48 657 Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician
49 658 Treatment Choice in Castration-resistant Prostate Cancer. *Eur Urol*. 2019: 2019: Oct 21.
50 659
51 659
52 659
53 659
54 659
55 659
56 659
57 659
58 659
59 659
60 659

660 52. Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al.
661 Defining Feasibility and Pilot Studies in Preparation for Randomised Controlled Trials:
662 Development of a Conceptual Framework. PLoS One. 2016;11(3).

664 53. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size
665 requirements to estimate key design parameters from external pilot randomised controlled
666 trials: a simulation study. Trials. 2014;15:264.

667 **Acknowledgments**

669 We would like to acknowledge the valuable support of the VARIANT Trial Oversight
670 Committee (TOC) members Dr Alison Tree, Dr Andrew Feber, Dr Rhian Gabe and our
671 patient representatives on this committee, Robin Millman and Paul Nash. We are grateful for
672 the assistance and support of our scientific collaborators Scott Dehm (University of
673 Minnesota), Luke Gaughan (NICR), Jun Luo (John Hopkins), Gert Attard (UCL) and the All
674 Wales Medical Genetics Laboratory (AWMGL).

675 Management of the study is by Newcastle University Clinical Trial Unit (NCTU).

676 **Authors' contribution**

677 Emma Clark: Conception and design of the work, data collection, drafting of the article,
678 critical revision of the article and final approval of the version to be published.

679 Miranda Morton: Trial management, data collection and drafting of the article.

680 Shriya Sharma: Trial management, data collection and drafting of the article.

681 Holly Fisher: Conception and design of the work, drafting of the article and critical revision
682 of the article.

683 Denise Howel: Data collection, drafting of the article, critical revision of the article and final
684 approval of the version to be published.

685 Jenn Walker: Trial management, data collection and drafting of the article.

686 Ruth Wood: Trial management, drafting of the article data collection, critical revision of the
687 article and final approval of the version to be published

688 Helen Hancock: Critical revision of the article and final approval of the version to be
689 published.

690 Rebecca Maier: Critical revision of the article and final approval of the version to be
691 published.

692 John Marshall: Conception and design of the work, critical revision of the article and final
693 approval of the version to be published.

694 Amit Bahl: Conception and design of the work.

695 Simon Crabb: Conception and design of the work and critical revision of the article.

696 Suneil Jain: Conception and design of the work and critical revision of the article.

1
2
3 697 Ian Pedley: Conception and design of the work.
4

5 698 Rob Jones: Conception and design of the work, data collection, drafting of the article, critical
6 699 revision of the article and final approval of the version to be published.
7

8 700 John Staffurth: Conception and design of the work, data collection, drafting of the article,
9 701 critical revision of the article and final approval of the version to be published.
10

11 702 Rakesh Heer: Conception and design of the work, drafting of the article, critical revision of
12 703 the article and final approval of the version to be published.
13

14 704 **Funding statement**

15
16 705 This work was supported by a National Institute for Health Research (NIHR) Research for
17 706 Patient Benefit (grant number PB-PG-0816-20043). The VARIANT trial is sponsored by
18 707 Newcastle upon Tyne Hospitals National Health Service Foundation Trust.
19
20

21 708 **Competing Interests Statement**

22
23 709 Dr. Jain reports personal fees from Astellas, personal fees from Bayer, personal fees from
24 710 Janssen, personal fees from Boston Scientific, personal fees from Almac Diagnostics,
25 711 personal fees from Sanofi Genzyme, personal fees from Movember, outside the submitted
26 712 work; Dr. Bahl reports research funding and advisory roles with Sanofi and Janssen and an
27 713 advisory role with Astellas and Bayer, outside the submitted work. Dr. Jones reports grants
28 714 and personal fees from Astellas, grants and personal fees from AstraZeneca, personal fees
29 715 and non-financial support from Bristol Myers Squibb, grants, personal fees and non-financial
30 716 support from Bayer, grants and personal fees from Exelixis, personal fees and non-financial
31 717 support from Janssen, personal fees and non-financial support from Ipsen, personal fees from
32 718 Merck Serono, personal fees and non-financial support from MSD, personal fees from
33 719 Novartis, personal fees from Pfizer, grants and personal fees from Roche, personal fees from
34 720 Sanofi Genzyme, personal fees from EUSA, outside the submitted work; .Prof. Staffurth
35 721 reports non-financial support from Bayer and personal fees from Janssen and Astellas outside
36 722 of the submitted work. Dr. Crabb has an honoraria/advisory role with Roche, Clovis
37 723 Oncology, Bayer, Janssen Cilag and Merck and receives research support from AstraZeneca,
38 724 Astex Pharmaceuticals and Clovis Oncology.
39
40
41
42

43 725 **Word Count (excluding title page, tables and reference list): 4, 446**
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 VARIANT trial consort diagram. Planned flow of participants throughout the VARIANT study. mCRPC, Metastatic Castrate Resistant Prostate Cancer; PSA, Prostate Specific Antigen; EORTC-QLQ-C30/PR25, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; AR-V7, Androgen Receptor Variant 7.

Supplementary Data – VARIANT Protocol

The constitution of the Trial Management Group (TMG): Chief Investigator(s), Sponsor representative, Co-Lead Investigator, Laboratory and Translational Science Lead, Statistician Lead, Trial Management Team, Co-Applicants and Collaborators who will attend TMG meetings as required.

The constitution of the Trial Oversight Committee (TOC) as a combined TOC whose members are independent of the trial: independent Chair, Independent Lab representative, Independent statistician and two independent patient representatives.

Roles and Responsibilities

Chief Investigator - Dr Rakesh Heer, Senior Lecturer and Consultant Urological Surgeon, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University

Co-Lead Chief Investigator - Prof. John Staffurth, Professor in Oncology and Consultant Oncologist, Velindre Cancer Centre, Cardiff University

Laboratory and Translational Science Lead - Dr Emma Clark, Translational Research Associate, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University

Principle Investigator - Prof Rob Jones, Professor of Clinical Cancer Research/ Honorary Consultant in Medical Oncology, University of Glasgow

Principle Investigator - Dr Ian Pedley, Clinical Director of NCCC and Clinical Oncologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust

Co-applicants – [1] Dr Amit Bahl, Senior Lecturer, Consultant Oncologist and Clinical Director, University Hospitals Bristol NHS Foundation Trust; [2] Dr Simon Crabb, Associate Professor and Honorary Consultant in Medical Oncology, University of Southampton; [3] Dr Suneil Jain, Senior Lecturer and Consultant in Clinical Oncology, Queen’s University Belfast.

PPI Representative - Dr John Marshall

Senior Statistician - Denise Howel, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University

Statistician - Dr Holly Fisher, Population Health Sciences Institute, Faculty of Medical Sciences,, Newcastle University

Data Manager – Ruth Wood, Newcastle Clinical Trials Unit, Newcastle University

Senior Trial Manager – Jenn Walker, Newcastle Clinical Trials Unit, Newcastle University

Supplementary Data – VARIANT Protocol

Joint Trial Manager - Dr Miranda Morton and Shriya Sharma, Newcastle Clinical Trials Unit, Newcastle University

Sponsor - The Newcastle upon Tyne Hospitals NHS Foundation Trust

Funder - National Institute for Health Research – Research for Patient Benefit

Out of Hours Contact - Dr Rakesh Heer, Newcastle University

Trial Oversight Committee (TOC) Chair - Dr Alison Tree, Uro-oncology Trials Team Leader and Consultant Clinical Oncologist, The Institute of Cancer Research

Recruitment and screening

Patients will be approached during routine clinic appointments from urology or oncology clinical services. Potentially eligible patients will have the trial explained to them, provided with a Patient Information Sheet (PIS) and their medical notes reviewed to establish if they are likely to be eligible to take part in the trial. In addition to assessing patient eligibility against the inclusion and exclusion criteria, a complete medical history including the patient's age and detailed information about their prostate cancer history and metastases will be collected after consent.

Consent Procedure

Full written informed consent will be received by signing, dating and initialling the consent form, which will be witnessed by a member of the research team, who has documented and delegated responsibility, and will check eligibility and counter-sign the consent form. The participant will specifically consent to; [1] their GP being contacted and informed of participation in the study; [2] access to relevant sections of their medical notes to carry out follow-up after the trial has ended; and [3] serial collection of blood samples for biomarker testing and storage in the Androgen Receptor Biology Bio-Bank (AR-3B) biobank for up to 10 years after the trial has ended.

Data collection methods

In addition to collecting standard care assessment of disease status data from intervention and control groups, trial specific questionnaire assessment (EORTC QLQ-C30 Quality of Life of Cancer Patients, EORTC QLQ-PR25 Quality of Life Prostate Cancer Module) and blood sample collection will take place at baseline, 12 and 24 week visits. Use of Health Services Questionnaire will be completed end of trial assessments. Participant data will only be identified using a unique individual participant identifier.

Standard care assessments:

The following clinical assessments will be conducted;

1. Cause of death (if appropriate)

Supplementary Data – VARIANT Protocol

- 2.
3. Evidence of PSA progression (>25% and >2 ng/mL above the nadir and confirmed by a second value >3 weeks later)
4. Clinical evidence of progression, stage and type of progression (biochemical, radiological or symptomatic)
5. Result of routinely collected PSA and testosterone measurements, full blood count and biochemistry tests
6. Details of anti-cancer therapy, including dates of treatments for ongoing anti-cancer therapy.

Questionnaires:

The EORTC quality of life questionnaire is an integrated system for assessing the health-related quality of life (QOL) of cancer patients participating in clinical trials. There is a set of core questions (QLQ-C30), supplemented by a prostate cancer specific module (PR25). PR25 is a diagnosis-specific module designed to be used in conjunction with the QLQ-C30, it is intended for use among a wide range of patients with prostate cancer varying in disease stage and treatment modality.

The QLQ-C30 consists of thirty questions incorporating; [1] functional scales, symptom scales and a number of items assessing additional symptoms commonly reported by patients with cancer, assessed on a four point scale and [2] a global health status/quality of life scale, assessed on a seven point scale. The PR25 module consists of 25 questions incorporating functional and symptom scales, all assessed on four point scale. The Use of Health Services questionnaire consists of ten questions assessing participant's use of health services over the course of their participation in the trial.

Data Management and Archiving

Data including the number of patients screened, approached and interested in taking part will be collected via a screening log. Trial and screening data is collected on electronic case report forms (eCRFs) using password limited access, secure web-based interface for data entry with inbuilt back-up facility, will be managed using a Clinical Data Management System (Elsevier's MACRO™) overseen by the Newcastle Clinical Trials Unit (NCTU). Individual access will be limited according to delegated roles and duties. Data will be handled, computerised and stored in accordance with the UK Data Protection Act 2018. All trial data will be retained in accordance with the latest Directive on GCP (2005/28/EC).

Participant clinical information will not be released without the written permission of the participant, except as necessary for monitoring and auditing by the Sponsor, its designee, Regulatory Authorities, the Trial oversight committee (TOC) or the Research Ethics Committee (REC). Trial data will be released to the trial statistician for analysis, to Paul O'Gorman Newcastle University biobank researchers after trial analysis and used in planning any future, definitive trial. All trial data will be stored for 10 years, in accordance with GCP and sponsor approved SOPs.

Supplementary Data – VARIANT Protocol


AR-V7 biomarker driven personalised treatment pipeline

Biomarker driven personalised treatment will be based on current scientific evidence from the Adnatest assay biomarker founding lab (John Hopkins, Baltimore, USA). A biomarker positive result is when a read is detected at 35 qPCR cycles or less and the recommendation will be to proceed with chemotherapy. A biomarker negative result is when a read is detected over 35 qPCR cycles (or there is no read at any qPCR cycle), and the recommendation will be to proceed with hormonal therapy (Enzalutamide or Abiraterone).

Participants will be required to give 30ml of blood at baseline (0 weeks), 12 weeks and 24 weeks. Samples will be routinely processed for biomarker read-out and AR-3B biobank storage at the Newcastle University central analysis lab as detailed in the VARIANT biomarker flow chart below. Following biomarker data analysis and data verification (according to sponsor agreed analytical and validation plan and SOPs), for participants randomised to the intervention standard treatment arm (AR-V7 biomarker guided), the baseline biomarker result and biomarker treatment recommendation will be sent securely within 10 working days to the local PI and delegated research staff. The PI and local trial team will then communicate with the participant regarding the biomarker guided treatment. Any modifications to the recommended treatment for participants will be made at the discretion of the treating clinician, based on their clinical judgement. Biomarker results from blood samples taken at weeks 12 and 24 will not be made available to the PI, local trial team or participant.

VARIANT Biomarker Flow Chart

Sample receipt, processing, analysis and reporting of biomarker read out



For participants randomised to the standard treatment arm (not AR-V7 biomarker guided), biomarker results will not be made available to the PI, local trial team or participant for any of the blood samples analysed (baseline, week 12 and week 24).

AR-V7 biomarker cross-site validation

An additional twenty participants selected at randomisation will provide a further (10ml) blood sample for cross site validation analysis of the biomarker at the Cardiff Central Analysis Lab using the commercially available AdnaTest ProstateCancerPanel AR-V7 circulating tumour cell (CTC) quantitative RT-PCR (RT-qPCR) assay (Qiagen®).

Androgen Receptor Biology driving hormone resistance

Research suggests that key ‘sub-populations’ or clones of molecular alterations (of which AR-V7 is an important subtype), compete with each other and are drivers of treatment resistance. In addition to performing AR-V7 biomarker assay, a fuller capture of AR-related CRPC biology will be achieved by collecting CTCs, plasma, buffy coat and red blood cell derivatives to compile an Androgen Receptor Biology Bio-Bank (AR-3B). Whole and CTC depleted blood sample derivatives will be collected and biobanked at 12 weekly intervals from baseline (prior to treatment) throughout follow up (to a maximum of 24 weeks +/- 2 weeks), including all trial captured data.

It is also important to acknowledge the expression of other AR splice variants are also associated with resistance to hormonal treatment(1,2), as are other AR pathway alterations such as AR mutations and amplifications(3). Ongoing discussions in the field as to the discriminatory value of solely detecting AR-V7 expression, may ultimately lead to a combination test that will improve treatment stratification and patient outcomes(4). However, at this time, AR-V7 remains the forerunner and a formal understanding of biomarker characteristics in the advanced prostate cancer treatment setting is required ‘to best inform’ a formal large-scale testing.

The AR-3B biorepository resource will be used to assess total VARIANT expression (capturing all VARIANTs in a single qPCR reaction) and explore (but not be limited to) AR hot spot mutations/sequencing/amplification and other mutations such as PTEN/p53/MYC gain/RB1 loss/MET gain/PARPi and further molecular pathways based on yet to be defined but new emerging data in time, in blood and blood derivatives.

This resource will provide added value to the feasibility study, by banking processed biomarker tissue for additional biomarker measures that may also contribute to hormone targeting resistance (or the emergence of biomarkers for chemo-sensitivity), and importantly be relevant in prostate cancer management. Blood samples will be transported, stored, accessed and processed in accordance with sponsor approved SOPs following appropriate legislation relating to the use and storage of human tissue for research purposes and such activities shall at least meet the requirements as set out in the 2004 Human Tissue Act and 2006 Human Tissue (Scotland) Act.

The results of any other research utilising blood samples (including those in the control arm), will not be reported back to the clinical team or to participants, this data is for research purposes only and will be published in appropriate peer reviewed scientific journals. Participants will remain anonymised in all publications.

Supplementary Data – VARIANT Protocol

Androgen Receptor Biology Bio-Bank (AR-3B) sample storage governance

Samples will be appropriately labelled in accordance with trial protocol as described in the current VARIANT trial site blood collection manual (Version 1.0 28th March 2019) to comply with the General Data Protection Regulation (GDPR) and Data Protection Act (GPA) 2018 and pseudo-anonymised with linkage to participant details possible only through the Participant Identification Log assessable only to delegated personnel. Sample shipment will be tracked and sample receipt at central analysis labs recorded using a specific sample collection MACRO™ database which is separate to the main trial database.

All AR-3B biobank samples are stored under HTA license 12534, under the Designated Individual, Dr. Christopher Morris (NICR). All samples are held under the custodianship of Mr. Rakesh Heer (Chief Investigator), who is responsible for the curation of these samples and ensuring compliance with the Human Tissue Act (2004) and GCP. Samples will be tracked and stored using Achiever medical LIMS.

Blood samples sent to the Cardiff Central Analysis Lab, will be consumed within 7 days of receipt and are not under the remit of the HTA. All RNA and DNA derivatives will be transferred to the Newcastle University AR-3B biorepository for storage at the end of the trial.

Supplementary Section References:

1. Van Etten JL, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, et al. Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer. *Cancer Res.* 2017;77(19):5228-35
2. Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. *Nat Commun.* 2016;7:13668
3. De Laere B, van Dam PJ, Whittington T, Mayrhofer M, Diaz EH, Van den Eynden G, et al. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. *Eur Urol.* 2017;72(2):192-200
4. Zhang J, Cunningham JJ, Brown JS and Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. *Nat Commun.* 2017;8(1):1861



To be printed on local headed paper

PATIENT INFORMATION SHEET

The Variant 7 Biomarker Feasibility Study

The VARIANT Study

We are inviting you to take part in a research study

Please read the following information to help you decide if you want to take part. It will explain why we are doing this research and what it might mean for you. You are free to decide whether or not to take part in this study. You do not have to decide straight away and you can talk to your friends/family about it. Ask us if you have any questions or you want to know more. If you choose not to take part, this will not affect the care you get from your doctors.

Study Summary

- In this study we will be taking 3 blood samples and asking patients to complete some questionnaires during their usual hospital appointments.
- Patients with **advanced metastatic prostate cancer** (cancer that has spread from the prostate to other parts of the body), often eventually stop responding to initial hormone therapy. After this point, treatment is usually with either:
 - 1) **Further hormonal treatment called next generation hormone treatment OR**
 - 2) **Non-hormonal treatment such as chemotherapy or radiotherapy**
- There is currently no clear guidance for which of these two different standard care treatment options a patient should receive.
- Testing the level of AR-V7 (a type of protein) in blood could suggest which of these two treatments patients will respond to best. The AR-V7 test is known as a biomarker test.
- VARIANT is looking to find out if the AR-V7 biomarker test is helpful to support doctors and patients in choosing between these treatment options.
- In this study, half of patients will receive treatment guided by the AR-V7 biomarker test. The other half will receive treatment as usual.

Please read the following information to see if you may be interested in taking part.

What is a biomarker test?

Biomarkers are substances that can be found and measured in parts of the body, in this case, the blood. Biomarker testing is a type of test that looks for these substances to give doctors information about a patient's health. **The AR-V7 blood test is a biomarker test looking for the AR-V7 protein.**

Why is VARIANT needed?

Initial treatments for advanced metastatic prostate cancer include hormone treatment alone or chemotherapy in combination with hormone treatment. Eventually most patients with advanced prostate cancer stop responding to initial hormone treatment. At this point, patients usually receive treatment with either further hormone treatment, known as next generation hormone treatment (such as abiraterone or enzalutamide), or with non-hormonal options (typically chemotherapy, or in some cases radium-223 radiotherapy). Although there are fewer side effects associated with next generation hormone treatment relative to chemotherapy, only 30-50% of patients will respond well to further hormone treatment.

The **AR-V7 biomarker is found in the blood** of some men who have received initial hormone treatment for prostate cancer. Recent studies have suggested that patients who have this biomarker in their blood may be less likely to respond well to advanced hormone therapy. Measuring the amount of this biomarker in blood (which is not usually tested for), may be useful to help guide choice of treatment for patients with advanced metastatic prostate cancer. We hope this will improve patient experience and outcome by spending less time on and experiencing side effects of treatments that might not work, starting a different treatment earlier, and potentially reduce the cost to the NHS.

The VARIANT study is a feasibility study in which we will look at whether doctors and patients are willing to use the results of this blood test to decide on a treatment option. At this stage we do not know that the AR-V7 biomarker will lead to patients having better responses to treatments. However, we hope that the results of VARIANT will help us to plan a similar, but larger, study to find out if the AR-V7 blood test does result in better outcomes for patients and whether AR-V7 testing should be used in standard NHS practice. We hope that 70 patients will take part in VARIANT.

Why have I been invited to take part?

You have been diagnosed with advanced metastatic prostate cancer and have already been treated with hormone therapy (also known as androgen deprivation therapy, or ADT). Your disease has stopped responding to the current therapy and you are due a change in treatment plan.

Do I have to take part?

No, it is up to you to decide if you want to take part in VARIANT. If you do not want to take part, you will still get the standard treatment that has been arranged by your treating doctor.

1 If you agree to take part, you can change your mind and withdraw from the study at any time
2 without having to give a reason.
3
4
5

6 **What does taking part involve?**

- 7 • If you decide to take part, you will be selected to have either:

8 **a) treatment guided by AR-V7 blood test result**

9 In this group, your treating doctor will receive the results of your AR-V7
10 blood test. Your treating doctor will tell you the result of the AR-V7 blood
11 test and discuss this with you before arranging a treatment option for you.
12 The results of the test may support you and your doctor in deciding whether
13 next generation hormonal therapy or non-hormonal therapy would be more
14 suitable for you.
15
16
17
18
19

20 **b) treatment as usual**

21 In this group, your doctor will arrange a treatment option with you as they
22 usually would if you were not in the study. You and your treating doctor will
23 NOT receive the results of your AR-V7 blood test. The results will only be
24 looked at by the trial management team at the end of the study.
25
26
27

- 28 • You will have equal chance of being in group a) or group b) (a 50:50 chance). Your
29 group will be selected by a computer. We call this 'randomisation'. Your doctor will
30 not have any say over which group you are in.
31
32
- 33 • It is important to note that we are not testing a new treatment in this study. All
34 VARIANT patients will receive one of the usual treatment options available to
35 patients in the NHS. The study is looking at whether doctors and patients are
36 willing to use the AR-V7 blood test and whether it is helpful in deciding **which**
37 treatment option is most suitable for individual patients.
38
39
40

41 **What will I have to do?**


42 A member of the VARIANT team will discuss the study with you and answer any questions
43 you may have. If you decide to take part, and your doctor confirms you are eligible for the
44 study, you will be asked to sign a consent form.
45
46
47

48 As well as receiving the treatment arranged with your doctor, taking part in the study will
49 mean (for ALL patients, that is patients in group a) and group b)):
50
51

- 52 • You will be asked to give a **blood sample on 3 occasions** (at the start of the
53 study, after 12 weeks and 24 weeks). We would like to collect around 20 ml of
54 blood (about 4 teaspoons full) each time.
55
56
- 57 • Some patients will be selected to give an **additional blood samples on one**
58 **occasion** (at the start of the study). We would like to collect around 10 ml of blood
59 (about 2 teaspoons full) for this sample. Patients will be randomly selected by a
60 computer system to give this additional blood samples. The doctor or a member of
their team will tell you if you have been selected to give this sample.

- On 2 of these visits, you will be asked to complete 2 **short questionnaires** about your quality of life. These will take around 15 minutes each to complete.
- Study visits will all take place during your usual hospital visits. There should be no extra visits to hospital required.
- We will use some information that is already collected about you as part of your standard clinical care. This includes information about your diagnosis, your treatment, results of scans and blood tests and your physical health. Taking part in VARIANT does not involve any extra scans to those you would receive normally.
- To take part in VARIANT, you will be asked to give your permission for your blood samples collected during this study to be stored at the Northern Institute of Cancer Research and used for future research as described below.

Study timeline in addition to standard treatment



What will happen to my blood samples?

Your blood samples will be tested for the AR-V7 biomarker at the Northern Institute for Cancer Research (NICR). If you are selected to give the additional blood sample this will be sent to the All Wales Medical Genetics Laboratory (AWMGL) for testing. You and your treating doctor will only find out the AR-V7 biomarker result if you are selected to have your treatment guided by the AR-V7 blood test result.

After the AR-V7 test, any remaining sample will be stored at the NICR biobank (a collection of samples) and will be used in future research to look at why people develop advanced prostate cancer and how cancer reacts to treatments. If you do not want your samples to be stored or used through the NICR biobank you will not be able to take part in this trial.

Your samples will be labelled with a unique study number. This number is used to link your sample back to you and only the study team and authorised people will be able to do this. Your sample will be sent with a form that includes your initials, date of birth and the date the sample was taken. This will help us make sure the samples can be linked back to the correct person.

For more detailed information about what will happen with your blood samples please see the section 'Further information about what will happen to blood samples' on page X, we recommend that you read this.

Expenses and payments

You will not receive payment for taking part in VARIANT. All parts of the study will happen when you are already coming to hospital for your usual visits.

What happens when the research study stops?

Your appointment at 24 weeks will be the last time we see you for the study. At the end of the study you will continue to receive usual clinical care as decided by your hospital and doctor. If appropriate, this may include continuing the anti-cancer drugs you are receiving, or changing to another if you and your doctor believe this to be in your best interests.

What are the possible risks and benefits of taking part?

Risks: Taking blood samples may cause some discomfort and minor pain, and occasionally patients can feel faint during or after. Sometimes patients will have some bruising where the blood has been taken. Only trained members of staff will perform the blood tests and every effort will be made to prevent any discomfort.

VARIANT patients will receive one of the usual treatment options available to patients in the NHS. Your doctor will be able to tell you more about possible side effects of these treatments. The risk of these treatments is the same as if you were not taking part in the study.

Benefits: By taking part in VARIANT, you will be helping us gather information to learn about using the AR-V7 biomarker to guide treatment for patients with advanced metastatic prostate cancer. We hope that we can improve the quality of life of patients in the future from VARIANT.

For some patients, taking part in the study will mean that your doctor receives your AR-V7 biomarker result before deciding on a treatment for you. This may help to inform which treatment would be best for you after reviewing your medical history.

If you want to find out more about taking part in research studies, you can visit the NHS Choices Website www.nhs.uk/conditions/clinical-trials/. On this website you will also find contact details for your local Patient Advice Liaison Service (PALS) office if you would like to speak to someone.

Further supporting information

What will happen if I do not want to carry on in the study?

You can withdraw your consent at any time and for any reason, without having to tell us your reason. You will be fully cared for and supported as per your hospital's standard practice.

We will ask if you are happy for us to:

- Use any information already collected about you.
- Continue using information collected as part of your usual care until the end of the study.

1 You can change your mind about allowing your stored blood samples to be used for
2 research at any time in the future, without giving any reasons, by contacting your local
3 study team as listed on page x. Any samples left at the NICR will be destroyed. Any
4 researchers to whom samples have been sent will be instructed to destroy the samples
5 they have in their laboratories. It will not be possible to withdraw any findings from
6 research work already undertaken using your donated samples.
7
8
9

10 **Can I take part in other research?**

11
12 If you are already taking part in a clinical trial we would look to see what the trial involved
13 and speak to the other trials team. We would need check that taking part in one trial would
14 not affect the treatment or results in the other.
15

16
17 If you take part in VARIANT and want to join another trial in the future, we ask that you
18 let the VARIANT team know so we can check with their team that there is no conflict. If
19 there was a conflict, the study team would discuss your options with you and you can
20 decide what it best for you.
21
22

23 **What if there is a problem?**

24
25 If you are not happy with any part of VARIANT, you should ask to speak to the study team
26 first who will do their best to help you. **Their contact details are on page X.** If you are still
27 unhappy you may wish to raise your concerns with someone who is not directly involved in
28 your care. You can contact the Patient Advice Liaison Service (PALS) who provide a
29 confidential service on <site to localise with phone number and email address>
30
31
32
33

34 In the unlikely event that you are harmed during the research and this is due to someone's
35 negligence (they were careless) you may have grounds for legal action for compensation,
36 but you may need to meet your own legal costs. NHS indemnity does not offer no-fault
37 compensation (for harm that is not anyone's fault).
38
39

40 **Will my GP be told about my involvement in VARIANT?**

41
42 Yes, with your permission we will inform your GP that you are taking part in VARIANT. We
43 will send you a copy of this letter so that you can see exactly what has been said. It will also
44 be noted in your hospital medical records so that staff in the hospital know you took part in
45 the study.
46
47
48
49

50 **What will happen to the results of the study?**

- 51 • The study is due to finish at the end of 2020.
- 52 • The results will be written in medical journals and presented in meetings to other
53 doctors, nurses and researchers.
- 54 • The anonymised data might be shared with other researchers and to help with future
55 studies. Your identity will always be protected.
- 56 • A report will be written by the study funder and put on their website.
- 57
- 58
- 59
- 60

- You may request a summary of the results at the end of the trial by contacting the study team, their details are on page X.

Will the information about me be kept confidential?

Yes. All of the information collected will be entered on computers that are kept secure and password protected.

- We will use a study number to identify you instead of using your name.
- Your contact details will never be shared with anyone else.
- You will not be named in any published results, reports or anything on our website.

The study information about you and your medical notes will be looked at by people directly involved in the study, clinical and lab staff as well as by people who are checking the study is running as it should. This may include the Newcastle Clinical Trials Unit at Newcastle University as they are managing the study. It may also include regulatory authorities, sponsor and funder.

Your local study team will collect information from you during the study. This will be entered onto a secure database using your study number instead of your name. Your local study team will be the only people that know that the study number refers to you. This means that the data on the database it is not identifiable to anyone outside of your local study team. The database is held by the Newcastle Clinical Trials Unit at Newcastle University. Access to this database is password protected and available to your doctors and research staff for the purpose of the trial. Data from the database will be analysed at the end of the whole study. Anonymised data from the database may be used when applying to carry out future related clinical trials or for other research projects related to prostate cancer.

After you have finished attending study visits, your local study team may review your health records and collect information for the study.

Data Protection

All of the data we collect will be kept strictly confidential and in accordance with the General Data Protection Regulation (GDPR).

We have included information on page X of this document that tells you how we do this and included some websites where you can find out more.

Who is organising and funding VARIANT?

The main study doctor (also called the 'Chief Investigator') is Mr Rakesh Heer, a Urological Surgeon at The Newcastle upon Tyne Hospitals NHS Foundation Trust. The study team includes senior doctors and nurses, university experts in research studies, and members of the public.

It is managed by the Newcastle University Clinical Trials Unit on behalf of the study sponsor – The Newcastle upon Tyne Hospitals NHS Foundation Trust. It is funded by the National Institute for Health Research, Research for Patient Benefit programme.

At least 3 hospitals will be taking part in VARIANT. Each hospital has a study doctor, called an 'Investigator'. The Investigator in your hospital is

Who has reviewed the study?

All research in the NHS is looked at by an independent group of people called a Research Ethics Committee. VARIANT has been reviewed and given a favourable opinion by the Wales REC 2 committee.

Patients have been involved in deciding how to do VARIANT from the start. For example, patients were involved in designing and applying for funding for the study, and continue to contribute as part of the study team. We also asked a group of patients and carers who have experienced cancer to look at the study information sheet to check the study is described in a clear way and is easy to understand.

What if relevant new information becomes available?

The treatment management of metastatic prostate cancer is changing all of the time. All VARIANT patients will receive one of the standard treatment options available in the NHS. This will include any new treatment options that become available while the study takes place.

Information gathered during the course of this study will be reviewed by an independent Trial Oversight Committee. The role of this group is to protect the safety and wellbeing of participants by making sure the study is running safely.

What if I have any questions?

Please ask the doctor or nurse who is looking after you. They can put you in touch with the research team or the Investigator for VARIANT at your hospital.

What happens next?

You can take time to think about the study and whether you want to take part. A member of the research team will speak to you when you come back in to discuss your treatment options. They will go through this information sheet with you and answer any questions before you make your final decision.

Thank you for taking the time to read this information sheet.

VARIANT team contact details for your hospital:

Principal Investigator:
Address:

Research Nurse:
Address:

Tel:

Tel:

GDPR and Transparency Information

The Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) is the sponsor for this study based in the United Kingdom and will act as the “data controller” for this study. **They are responsible for looking after your information and using it properly.**

This study is managed on behalf of the sponsor by the Newcastle Clinical Trials Unit who will act as the “data processor”. As data processor, this means that we are responsible for processing personal data on behalf of a controller. We will be using information from you in order to undertake this study, and will keep identifiable information about you for 10 years.

Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the least amount of personally-identifiable information possible.

You can find out more about how your information is used at http://www.newcastle-hospitals.org.uk/about-us/freedom-of-information_how-we-use-information

To find out more about research and general use of patient information please refer to the Health Research Authority Website <https://www.hra.nhs.uk/information-about-patients/>

The sponsor as an NHS Organisation and the Newcastle Clinical Trials Unit as a University use personally-identifiable information to conduct research to improve health, care and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when we use personally-identifiable information from people who have agreed to take part in research. This means that when you agree to take part in a research study, we will use your data in the ways needed to conduct and analyse the research study.

Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the interests of society as a whole. We do this by following the [UK Policy Framework for Health and Social Care Research](#).

If you wish to raise a complaint on how we have handled your personal data, you can contact our Data Protection Officer who will investigate the matter. If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful you can complain to the Information Commissioner’s Office (ICO).

The sponsor Data Protection Officer is Richard Oliver and you can contact them at nuth.dpo@nhs.net.

The local study team at your hospital will collect information from you and/or your medical records for this research study in accordance with our instructions.

The local study team will use your name, NHS number and contacts details to contact you about the research study, and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study. Individuals from the sponsor, Newcastle Clinical Trials Unit and regulatory organisations may look at your medical and research records to check the accuracy of the research study. The local

1 study team will pass these details to the sponsor or the Newcastle Clinical Trials Unit
2 along with information collected from you and/or your medical records. The only people
3 at sponsor or the Newcastle Clinical Trials Unit who will have access to information that
4 identifies you will be people who need to contact you or audit the data collection process.
5 The people who analyse the information will not be able to identify you and will not be
6 able to find out your name, NHS number or contact details.
7

8
9 The local study team will keep identifiable information about you from this study for 10
10 years after the study has finished.
11

12 When you agree to take part in a research study, the information about your health and
13 care may be provided to researchers running other research studies in this organisation
14 and in other organisations. These organisations may be universities, NHS organisations
15 or companies involved in health and care research in this country or abroad. Your
16 information will only be used by organisations and researchers to conduct research in
17 accordance with the UK Policy Framework for Health and Social Care Research.
18
19

20 This information will not identify you and will not be combined with other information in a
21 way that could identify you. The information will only be used for the purpose of health
22 and care research, and cannot be used to contact you or to affect your care. It will not be
23 used to make decisions about future services available to you, such as insurance.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Further information about what will happen to blood samples

- Your samples will be sent securely to the Northern Institute of Cancer Research (NICR) for testing. For selected patients, a sample will also be sent to the All Wales Medical Genetics Laboratory (AWMGL) for testing (to confirm the results of the biomarker test).
- At the start of the study, your blood sample will be tested for the AR-V7 biomarker. Your doctor will receive the result of this test if you are in the group receiving treatment guided by AR-V7 blood test result. If you are in the treatment as usual group neither you nor your doctor will receive the result of the test.
- We may also test your blood sample for the AR-V7 biomarker at the end of the trial. These results will be used to inform the research. Neither you nor your doctor will not receive these results.
- Your blood samples will be stored at the NICR biobank (a collection of samples) and will be used in future research to look at why some patients develop advanced prostate cancer or how the cancer reacts to treatment. The DNA and RNA (the genetic material inside a cell), will be taken out of these stored samples and will also be stored at the NICR biobank. If you do not want your samples to be stored or used through the NICR biobank you will not be able to take part in this trial.
- Although unlikely for the VARIANT trial, there is a small possibility that your blood samples which have been stored in the NICR biobank may be used in research involving rodents (rats or mice). This is only done when it is essential to further our understanding of the way in which a disease develops or responds to treatment. These experiments are performed according to strict guidelines set out by the government and involve minimal stress to the rodents. **If you do not wish for your samples to be used in research using animals you should not complete the box referring to this on the consent form we will ask you to sign.** If you do not consent to your samples being used in research using animals you will still be able to participate in the VARIANT trial.
- If you are selected to provide an additional sample to be sent to AWMGL, the DNA and RNA (the genetic material inside a cell) may be taken out and stored at AWMGL before being transferred to the NICR biobank.
- You and your doctor will not find out the results of any tests done on your stored blood samples. Results of future research with your stored samples will be used to improve care of patients with advanced prostate cancer in the future.
- Your blood samples will be labelled with a unique study number. This number is used to link your sample back to you and only the study team and authorised people will be able to do this. Your sample will be sent with a form that includes your initials, date of birth and the date the sample was taken. This will help us make sure the samples can be linked back to the correct person which is especially important for feeding back the test results.
- Your stored samples may be used by researchers in the UK or overseas (including USA or Europe). Commercial partners may also use your samples for research

1 purposes. In most cases the commercial partners will be small companies that
2 were started in universities (university/academic spin-off companies), or drug
3 companies. Working with commercial partners is often important to have the
4 resource to develop tests or products. We will ask partners to sign a legal contract
5 to make sure samples are handled appropriately. Although the research will not be
6 conducted to make money, it is possible that some of the results will be of value to
7 commercial companies, for example in the development of new tests or treatments
8
9

- 10 • Any money made by sending samples to commercial laboratories will be put in to
11 local research or used to improve patient care. Under UK law, sample donors are
12 not entitled to a share of any profits that may result from this activity.
13
- 14 • The samples will be destroyed after 10 years of the last follow up for the last patient
15 enrolled in the study. This will include all the blood samples and any linked data.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Consent Form



To be printed on local headed paper

The Variant 7 Biomarker Feasibility Study

The VARIANT Study

PATIENT CONSENT FORM

Site ID number:

Participant ID Number:

Principal Investigator Name: _____

Please INITIAL these boxed if you agree:

1. I have read and understood the Patient Information Sheet version _____ dated _____ for the above study. I have had the opportunity to consider the information, ask questions and I am happy with the answers given.	
2. I understand that I do not have to take part in this study. I know that I can withdraw at any time without giving a reason and without my medical care or legal rights being affected.	
3. I understand that information about me will be collected, recorded and used for this study unless I withdraw my consent. I understand that my information will be kept securely and confidentially.	
4. I agree for a copy of my consent form to be sent securely to the Newcastle University Clinical Trials Unit for checking.	
5. I agree to my General Practitioner (GP) being informed about me taking part in this study.	
6. I understand that relevant sections of my medical notes and information collected during the study may be looked at by people from Newcastle Clinical Trials Unit, the study sponsor, regulatory authorities and the local NHS Trust, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.	

Consent Form

7. I understand that any personal information collected for the study will be kept confidential and not be made public. I understand that anonymised data from the study may be used for other research projects related to prostate cancer and will be published in medical journals, at research meetings and shared with other researchers.

8. I consent to relevant sections of my medical notes being accessed by members of my local study team to carry out follow-up, including after my participation in the trial has ended, and for there to be a link between my healthcare records and the data collected for the trial.

Sample collection

9. I consent to the collection of my blood samples as described in the VARIANT patient information sheet and understand that my samples will be sent to the Northern Institute of Cancer research (NICR) and the All Wales Medical Genetic Lab (AWMGL) for testing.

10. I understand that my samples will not be identifiable except to the trial management team and I give permission for my date of birth and initials to be sent with the blood samples to the lab and with the biomarker result to my study doctor.

11. I consent to my samples being stored in the NICR biobank for up to 10 years, and give permission for samples to be used as described in the VARIANT Patient Information Sheet. I understand that the biobank will keep my identity confidential and any information collected about me during the study will be anonymised in a way that protects my identity.

12. OPTIONAL: I consent to my samples to be used in experiments using rodents (rats or mice).

Agree to Participate

13. I agree to take part in the VARIANT study.

Name of patient

Signature

Date

Name of Person

Signature

Date

Consent Form

1
2 **taking consent**
3
4

5 **When completed: 1 copy for participant; 1 copy (original) for Investigator Site File; 1 copy to be kept**
6 **in medical notes and 1 copy to be sent securely to Newcastle Clinical Trials Unit**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 Completed SPIRIT checklist for VARIANT trial protocol submission:
4

5 Administrative Information:

- 6
7 1. Title
8 2. Trial Registration
9 3. Protocol Version
10 4. Funding
11 5. Roles and Responsibilities

12 Introduction:

- 13
14 6. Background and Rationale
15 7. Objectives
16 8. Trial Design

17
18 Methods: Participants, interventions, Outcomes

- 19
20 9. Study Setting
21 10. Eligibility criteria
22 11. Interventions
23 12. Outcomes
24 13. Participant timeline
25 14. Sample size
26 15. Recruitment

27
28 Methods: assignment of interventions (for controlled trials)

- 29
30 16. Allocation
31 17. Blinding (masking)

32 Methods: data collection, management, analysis

- 33
34 18. Data collection methods
35 19. Data management
36 20. Statistical methods

37
38 Methods: monitoring

- 39
40 21. Data monitoring
41 22. Harms
42 23. Auditing

43 Ethics and dissemination:

- 44
45 24. Research ethics approval
46 25. Protocol amendments
47 26. Consent or assent
48 27. Confidentiality
49 28. Declaration of interests
50 29. Access to data
51 30. Ancillary and post-trial care
52 31. Dissemination policy

53
54 Appendices

- 55
56 32. Informed consent materials
57 33. Biological specimens
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only